Entities

Tine Bjerregaard is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forEducation Admissions. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Lotte Enevold Snedker is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forIT, Operations and Projects. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Rojbin Cutcu is listed by Cambridge Innovation Capital as receptionist and office administrator. Joined CIC in 2024, bringing real-estate and diagnostic-service administration experience; studied sociology at Anglia Ruskin University. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Sam Sturge is listed by Cambridge Innovation Capital as non-executive director. Cambridge University Investment Management executive with private-equity and venture experience from Partners Capital and Morgan Stanley. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Tue Vinther-Jørgensen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forReform Implementation. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Morten Rasmussen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forIT, Operations and Projects. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Ruth Aspel is listed by Cambridge Innovation Capital as group financial controller. Joined CIC in 2024; accounting experience spans payments and clinical AI technology businesses. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Sylwia Szulc is listed by Cambridge Innovation Capital as finance manager. Joined CIC in 2019; qualified accountant with an academic background in marketing in Poland. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Gorm Kofoed Petersen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forEU, International Affairs and Space. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Tom Page is listed by Cambridge Innovation Capital as head of investor relations. Investor-relations specialist with previous UK government science-policy, Office for Investment and 3i experience; trained in engineering at Cambridge. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Adam Glinsman is listed by Cambridge Innovation Capital as advisory panel member. Finance and investment executive with previous Cantab, GAM and Lansdowne operational leadership. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Anders Ødegaard is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forEU, International Affairs and Space. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Anette Dørge is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forEducation Assessment and Accreditation. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Victoria Woodward is listed by Cambridge Innovation Capital as head of business support. Business-support leader with prior project-management experience at PA Consulting, OC&C and Tyndall. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Erik Langaker is listed by Cambridge Innovation Capital as advisory panel member. Technology investor and entrepreneur, including previous Pragmatic chairmanship and private-equity experience. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Jens Storm is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forData. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Mikkel Buchter is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forEducation Assessment and Accreditation. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Bente Olsen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forLegal Affairs. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Gregory Winter is listed by Cambridge Innovation Capital as advisory panel member. Nobel laureate whose antibody research underpins therapeutic biotechnology; founded Cambridge Antibody Technology, Domantis and Bicycle-related ventures. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Jette Esager Rasmussen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forInternational Mobility (acting). The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Andreas Stubberup Waagner Nielsen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forFinance and Accounting. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Heiner Dreismann is listed by Cambridge Innovation Capital as advisory panel member. Former Roche diagnostics leader with PCR, molecular-biology and medical-industry experience. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Ajay Chowdhury chairs the Cambridge Enterprise board. His role provides governance of the university-owned commercialisation and investment subsidiary.

Anthony Odgers is listed by Cambridge Enterprise as University Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Ben Alexander is listed by Cambridge Enterprise as External Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

David Washburn is listed by Cambridge Enterprise as External Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Debu Purkayastha is listed by Cambridge Enterprise as External Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

John Aston is listed by Cambridge Enterprise as University Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them. John Aston is listed by Cambridge Innovation Capital as non-executive director. Cambridge pro-vice-chancellor for research and professor of statistics, with research including statistical neuroimaging. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

John Lee (DisplayLink) is listed by Cambridge Innovation Capital as advisory panel member. Former DisplayLink chief financial officer from 2011 to July 2020 and former Velocix chief executive, with extensive Cambridge semiconductor and technology experience. He is distinct from the John Lee at Zero Infinity Partners/NerdWallet. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Kimberley Mensah is listed by Cambridge Enterprise as People Lead. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Laura Diaz Anadon is listed by Cambridge Enterprise as Academic Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Laura Escobar is listed by Cambridge Enterprise as TenU Team Assistant. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Patrick Maxwell is listed by Cambridge Enterprise as Academic Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Pippa Browne is listed by Cambridge Enterprise as Senior Strategic Communications Advisor (TenU). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Róisín Owens is listed by Cambridge Enterprise as Academic Non-Executive Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Sofia Spiegel-Renshaw is listed by Cambridge Enterprise as Operations Assistant. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Yu Zhou (Angelina) is listed by Cambridge Enterprise as Marketing & Partnerships Executive. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Jesper Risom is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forGrant Programmes and Independent Research Fund Denmark. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Ellie Greatorex is listed by Cambridge Enterprise as Events Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Emily Turner is listed by Cambridge Enterprise as Senior Marketing and Communications Executive. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Eva Maciag is listed by Cambridge Enterprise as Events & Creative Executive. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Gianluca D’Uva is listed by Cambridge Enterprise as Senior Marketing and Communications Executive. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Kara Wells is listed by Cambridge Enterprise as Marketing and Communications PA. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Lexi Radcliffe-Hart is listed by Cambridge Enterprise as Communications Manager (Digital). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Leyla Gezer is listed by Cambridge Enterprise as Mid-Weight Designer. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Tegen Amos is listed by Cambridge Enterprise as Creative Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Nicolai Ebsen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forGovernance and Supervision. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Alexandra Canet Font is listed by Cambridge Enterprise as Communications Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Anca Weldon is listed by Cambridge Enterprise as IT Support Analyst. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Chris Nutt is listed by Cambridge Enterprise as IT Systems and Security Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Ian Everett is listed by Cambridge Enterprise as Artificial Intelligence Lead. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Keith Peters is listed by Cambridge Innovation Capital as advisory panel member. Former Cambridge Regius Professor of Physic from 1987 to 2005, with a research background in immunology. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Leila Guichard is listed by Cambridge Enterprise as Marketing & Events Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Maruf Ahmed is listed by Cambridge Enterprise as IT Support Analyst. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Michael Yardley is listed by Cambridge Enterprise as IT Support Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Richard Brown is listed by Cambridge Enterprise as Application Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Abdulmalik Abdullahi Shinkafi is listed by Cambridge Enterprise as AI Integration Engineer. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

David Walsh is listed by Cambridge Enterprise as Head of IT. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Kerry Walton is listed by Cambridge Enterprise as Executive Assistant to CEO. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Matthew Wheeler is listed by Cambridge Enterprise as Credit Controller. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Rosemary Boyle is listed by Cambridge Enterprise as General Counsel (Intellectual Property). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Sinead Varley is listed by Cambridge Enterprise as Office & Facilities Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Steven Humm is listed by Cambridge Enterprise as Finance Administrator. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Susan Hands is listed by Cambridge Enterprise as Purchase Ledger Administrator. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Abigail Swadling is listed by Cambridge Enterprise as Finance Business Partner. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Alessandro Coppola is listed by Cambridge Enterprise as Assistant Finance Business Partner. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Denise Champion is listed by Cambridge Enterprise as Business Support Coordinator (AHSS). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Diane Gaskin is listed by Cambridge Enterprise as Head of Finance. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Elizabeth Bone is listed by Cambridge Enterprise as Financial Accountant. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Gitte Agerhus is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forGovernance and Supervision. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Isak Ouariache is listed by Cambridge Enterprise as Junior Business Intelligence Analyst. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Julie Boulton is listed by Cambridge Enterprise as Post Deal Coordinator. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Natalie Kirsch is listed by Cambridge Enterprise as IP Coordination Team Lead (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Amy Reed is listed by Cambridge Enterprise as Post Deal Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Angeline Gunaseelan is listed by Cambridge Enterprise as IP Portfolio Coordinator (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Boris Bouqueniaux is listed by Cambridge Enterprise as Head of Business Support. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Connor Farrell is listed by Cambridge Enterprise as Manager, Early Talent. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Dan Drew is listed by Cambridge Enterprise as Senior Business Intelligence Developer. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Kieran Murphy is listed by Cambridge Innovation Capital as advisory panel member. Previously led GE Healthcare until December 2021; CIC’s biography also records life-science technology board experience. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Laura Skinner is listed by Cambridge Enterprise as PA & Strategic Projects Support, EIP. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Winny Sanchita is listed by Cambridge Enterprise as Manager, Accelerator. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Jason Amartey is listed by Cambridge Enterprise as Investment Analyst. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Kristiane Frost Thorius is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forHuman Resources. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Leila Karass is listed by Cambridge Enterprise as Paralegal. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Mahesh Santiapillai is listed by Cambridge Enterprise as Investment Manager (Software & DeepTech). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Matt Doorbar is listed by Cambridge Enterprise as Legal Counsel. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Megan Meredith-Rodriguez is listed by Cambridge Enterprise as Investment Associate (Deep Tech). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Piers Horlock is listed by Cambridge Enterprise as Investment Associate. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Stefan Galander is listed by Cambridge Enterprise as Investment Associate. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Vicky McDonnell is listed by Cambridge Enterprise as Ventures PA. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Amanda Wooding is listed by Cambridge Enterprise as Deputy Head of Ventures. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Christine Waterman is listed by Cambridge Enterprise as Ventures PA and Data Administrator. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Gemma Siddall is listed by Cambridge Enterprise as Senior Investment Associate (Sustainability). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Mark Lewisohn is listed by Cambridge Innovation Capital as advisory panel member. Investment banker and chartered accountant with technology-sector experience and published University of Cambridge council involvement. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Samuel Daffern is listed by Cambridge Enterprise as Senior Translation Associate. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Sophie Jones is listed by Cambridge Enterprise as Senior Commercialisation Associate (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Suzy Dilly is listed by Cambridge Enterprise as Associate Director (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Usman Munir is listed by Cambridge Enterprise as Commercialisation Manager (Deeptech & Software). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Zoe Parry is listed by Cambridge Enterprise as Senior Commercialisation Associate (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Matt Wells is listed by Cambridge Enterprise as Senior Commercialisation Associate (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Matthew Newman is listed by Cambridge Enterprise as Associate Director (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Mei Hong is listed by Cambridge Enterprise as Senior Commercialisation Associate (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Morag Nixon is listed by Cambridge Enterprise as Senior Commercialisation Associate (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Nathalie Muller is listed by Cambridge Enterprise as Senior Commercialisation and Outreach Manager (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Oleksandra Korychenska is listed by Cambridge Enterprise as Technology Development & Project Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Poppy Nicholson is listed by Cambridge Enterprise as Technology Development & Licensing PA. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Rachel Atfield is listed by Cambridge Enterprise as Associate Director (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Jennie Flint is listed by Cambridge Enterprise as Associate Commercialisation Director (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Jennifer Bromley is listed by Cambridge Enterprise as Commercialisation Manager (Agri-tech) CERES. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Kate Dulwich is listed by Cambridge Enterprise as Associate Business Development Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Laura Donnelly is listed by Cambridge Enterprise as Associate Director (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Lewis Kearsey is listed by Cambridge Enterprise as Senior Commercialisation Associate (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Louise Sutherland is listed by Cambridge Enterprise as Ceres Project Development Director. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Maria Aspioti is listed by Cambridge Enterprise as Technology Development & Project Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Marina Avena Maia is listed by Cambridge Enterprise as Senior Commercialisation Associate (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Martin Frost is listed by Cambridge Innovation Capital as advisory panel member. Co-founded CMR Surgical in 2014 and previously led the company as chief executive, helping develop the Versius surgical robotics platform. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Trine Søndergaard is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forHead of Press and Communications. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Ellie Thompson is listed by Cambridge Enterprise as Commercialisation Associate (Arts, Humanities and Social Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Emma Garfield is listed by Cambridge Enterprise as Senior Commercialisation Manager (Agri-Tech) CERES. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Emma Lawrence is listed by Cambridge Enterprise as Senior Commercialisation Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Farah Al-Naimi is listed by Cambridge Enterprise as Associate Director (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Hannah Pape is listed by Cambridge Enterprise as Associate Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Helen Young is listed by Cambridge Enterprise as Commercialisation Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Ione Meyer is listed by Cambridge Enterprise as Senior Commercialisation Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

James Camp is listed by Cambridge Enterprise as Commercialisation Associate (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Lise Jürgensen is named by the Danish Agency for Higher Education and Science in itsorganisation chart effectiveOctober1,2026 forManagement Secretariat. The agency is a Danish state administrative unit, CVR34042012, responsible for research, higher education and knowledge-based innovation administration. This is the published professional unit/function affiliation, rather than an invented additional civil-service rank, exact appointment date or personal investment authority. Further own career biography and an authentic individual headshot were not publicly provided in the audited current directory/chart.

Annika Friberg is listed by Cambridge Enterprise as Senior Commercialisation Associate (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Arnie Patel is listed by Cambridge Enterprise as Senior Commercialisation Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Catherine Eyre is listed by Cambridge Enterprise as Senior Commercialisation Manager (Agri-Tech) CERES. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Dafne Chirivino is listed by Cambridge Enterprise as Associate Business Development Director (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Daisy Wraight is listed by Cambridge Enterprise as Business Administration Apprentice. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Daniela Lobo is listed by Cambridge Enterprise as Technology Development & Project Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Dominic Chivers is listed by Cambridge Enterprise as Commercialisation Manager (Arts, Humanities and Social Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Ellie Reid is listed by Cambridge Enterprise as Associate Commercialisation Manager (Physical Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Amy Lam is listed by Cambridge Enterprise as Senior Commercialisation Manager (Life Sciences). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Anna Waldock is listed by Cambridge Enterprise as Administrative Team Lead (TD&L). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Emma Salgård Cunha is listed by Cambridge Enterprise as Director of DeepTech & Software. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Gillian Davis is listed by Cambridge Enterprise as Commercialisation Director, Deputy Head of Physical Sciences. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Phil Elstob is listed by Cambridge Enterprise as Senior Commercialisation Director (LS). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Sophie Appleby is listed by Cambridge Enterprise as Operations and Project Manager (ideaSpace West). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Terry Parlett is listed by Cambridge Enterprise as Senior Commercialisation Director (LS). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Tom Mentlak is listed by Cambridge Enterprise as Head of Technology Investment Fund. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Annemarie Falktoft is Deputy Director of the Danish Agency for Higher Education and Science from2022, with published responsibility for research and knowledge-based innovation. Her official biography records leading research/innovation policy in the Ministry of Higher Education and Science2018–2022 and its ministerial/management secretariat2016–2018, earlier officer and consultant roles in that ministry2012–2016 and the University and Property Agency2008–2012, and policy-coordinator service at ETUCE-CSEE2004–2008. The agency publishes her authentic named portrait; her exact2022 appointment day is unpublished.

Kirsten Batcheler is listed by Cambridge Enterprise as Membership, Marketing and Office Manager (ideaSpace City). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Maitena Fernandez Gonzalez is listed by Cambridge Enterprise as Office and Events Manager (ideaSpace West). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Marina Gonzalo Soares is listed by Cambridge Enterprise as Global Outreach Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Oakley Carr is listed by Cambridge Enterprise as Senior Global Outreach Executive. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Oliver Paul is listed by Cambridge Enterprise as Global Outreach Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Richard Palmer is listed by Cambridge Enterprise as Enterprise Education Lead. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Sarah Ranchev-Hale is listed by Cambridge Enterprise as Director of Entrepreneurship. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Saran Mullen-Yates is listed by Cambridge Enterprise as Operations Manager. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Steve Leonard is listed by Cambridge Innovation Capital as advisory panel member. Technology executive with experience across Asia and Europe; CIC’s biography records Singularity leadership, which is not independently treated as a current outside appointment. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Ben Hartley is listed by Cambridge Enterprise as Director of ideaSpace. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Georgina Hall is listed by Cambridge Enterprise as EIP Events and Administration Lead. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Helen Alexander is listed by Cambridge Enterprise as Director of IE Cambridge. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Peri Cihan is listed by Cambridge Enterprise as Associate Director (Consultancy). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Siân Fogden is listed by Cambridge Enterprise as Associate Director (Research Tools). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Tania Gonzalez Duran is listed by Cambridge Enterprise as Senior Commercialisation Associate (Consultancy). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Yvette Edwards is listed by Cambridge Enterprise as Senior Administration Coordinator (Consultancy Services & Research Tools). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Billy Davies is listed by Cambridge Enterprise as Associate Commercialisation Manager (Research Tools). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Francesca Melle is listed by Cambridge Enterprise as Senior Commercialisation Associate (Research Tools). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Helena Did-Dell is listed by Cambridge Enterprise as Administrative Team Lead (Consultancy & Research Tools). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Kirsty Latto is listed by Cambridge Enterprise as Commercialisation Manager (Consultancy). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Magda Ali is listed by Cambridge Enterprise as Senior Commercialisation Associate (Consultancy). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Alexander Seddon is listed by Cambridge Enterprise as Associate Commercialisation Manager (Consultancy). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Anne Sablonniere is listed by Cambridge Enterprise as Commercialisation Manager (Consultancy). This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Helen Atkinson is listed by Cambridge Enterprise as Deputy Head of Consultancy Services. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Michelle Zappala Wood is listed by Cambridge Enterprise as Head of People and Culture. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Tabitha Goldstaub is listed by Cambridge Innovation Capital as advisory panel member. Co-founded CogX and Rightster and writes about artificial intelligence; the published biography also records her UK AI Council leadership, without establishing its current tenure. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Amanda Zeffman is listed by Cambridge Enterprise as Head of Consultancy Services and Research Tools. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Ane Sofie Hansen is Deputy Director of the Danish Agency for Higher Education and Science, serving from2025 with published responsibility for data, law, financial management and service. Her official biography records chief-of-staff/group-supervision leadership in the Food Ministry2021–2025, corporate-development leadership in the Danish National Police2020–2021, tax-ministry/tax-agency leadership2016–2020, social-ministry/appeals-board consulting2011–2016, Banedanmark2010–2011, and Ministry of Finance2007–2010. Her original named agency portrait is preserved; a precise2025 appointment day is unpublished.

Caroline Hyde is listed by Cambridge Enterprise as Head of Entrepreneurship and Ecosystems. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Christine Martin heads Cambridge Enterprise Ventures, the university spinout investment team. Her published profile covers early-stage technology investment and the development of research-led companies.

Declan Weldon is listed by Cambridge Enterprise as Head of Technology Development & Licensing. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Jim Glasheen leads Cambridge Enterprise as Chief Executive. His previous work includes founding biotechnology businesses Atalanta and Clade, university innovation leadership at UMass, and life-science venture investing with Technology Partners.

Joanna Tramontin is listed by Cambridge Enterprise as Head of Marketing and Communications. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Lore Lippmann is listed by Cambridge Enterprise as Chief Financial Officer. This published affiliation belongs to the university’s commercialisation subsidiary; it does not imply employment by its portfolio companies or personal investment in them.

Paul Seabright is Executive Director of Cambridge Enterprise, working across the university’s research commercialisation activities.

Ted Briscoe is listed by Cambridge Innovation Capital as advisory panel member. Cambridge computational-linguistics researcher whose work covers speech, natural-language processing and statistical language understanding. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Julie Lungholt is Director of the Danish Agency for Higher Education and Science from September2026. The agency’s official career biography records earlier director service in the Ministry of Higher Education and Science2023–2026, deputy director at DanmarksRadio2020–2023, division-head roles in the Ministry of Taxation2018–2020 and the Ministry for Children, Education and Gender Equality2015–2018, chief consultant in the Ministry of Finance2009–2015, and administrative-officer service in the Agency for Governmental Management2007–2009. The agency supplies her authentic official photograph; September2026 appointment month is established, precise day unpublished.

Tim Garnett is listed by Cambridge Innovation Capital as advisory panel member. Former Eli Lilly chief medical officer from 2008 to 2021, with clinical-development, pharmacovigilance and regulatory experience; trained in medicine and obstetrics/gynaecology. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

The Danish Agency for Higher Education and Science (Uddannelses- og Forskningsstyrelsen, UFS) is a Danish state administrative agency, CVR 34042012, headquartered at Haraldsgade 53, 2100 Copenhagen Ø. Its official contact page confirms the agency identity, grants-payment EAN 5798000416697 and that UFS-IT uses the same CVR. As of October 2026 it operates under the Ministry of Research, Education and Digitalisation; the ministry and agency remain separate administrative identities. The current combined agency was created on 1 October 2020 by merging the Agency for Institutions and Educational Grants with the Agency for Science and Higher Education. Earlier predecessor registry dates are distinguished from this agency's creation. Its website ufsn.dk launched in December 2025; historical ufm.dk records remain primary sources. It administers legal frameworks and state appropriations for research, higher education, knowledge-based innovation and international cooperation, oversees institutions, and serves as Denmark's national space authority. These functions support AI, deep technology and life-science research. Its updated purpose page records that payment of SU, transport discounts and SVU transferred on 1 October 2026 to Udbetaling Danmark and Arbejdsgivernes Uddannelsesbidrag. Those former responsibilities are not presented as unchanged current duties. gMendel's 2022 review and ecosystem page identify actual agency support alongside Innovation Fund Denmark and private investors. Its own one-page presentation describes an agency grant awarded in April 2022, separately from Innovation Fund Denmark support in May 2022, Eurostars and Innowwide. The presentation's aggregate USD 900,000 across grants is not an individual agency award or paid-to-date amount. The specific scheme, contract, allocation and precise payment date remain unpublished; the company link preserves a source-reported grant with unknown structured cash/date. Innovation Fund Denmark and Eureka Network AISBL remain separate verified institutions, and agency administration does not create duplicate presumed payments from their awards. Julie Lungholt became Director in September 2026, with current deputy directors Ane Sofie Hansen and Annemarie Falktoft. The organisation chart effective 1 October 2026 names 21 professionals, and the press directory adds Morten Bakkær Steen, giving 22 published people in scope. The vacant deputy-director box marked NN is excluded. The official logo and three current executive portraits and career biographies were verified from original agency media. For the other 19 named people, the current chart/press directory establishes their function but does not supply an authentic portrait or expanded career biography; these gaps are explicit. Older Hans Müller Pedersen-led charts are historical, and chart observation dates are not appointment dates. The institution is a Company-typed public agency and qualified support provider, rather than an LP venture manager. State appropriations, administered grant budgets, programme targets and research-fund secretariat services are not fund closes, AUM or paid company equity. The chart's Independent Research Fund Denmark function does not collapse that separately governed fund into the agency or prove that all its recipients received agency cash checks.

Published by the manager as a member of the crypto-native investment team at its first Web3 fund close. Current Heartcore membership is unverified because he is absent from the current published roster.

Published returning in March2023 as Principal in Stockholm. Current Heartcore membership is unverified because he is absent from the current published roster.

Published as a Heartcore team member contributing research on the AI orchestration layer; precise job title is unproven. Current Heartcore membership is unverified because he is absent from the current published roster.

Published joining in August2023 as an analyst in the Web3 team. Current Heartcore membership is unverified because he is absent from the current published roster.

Published joining in October2023 for growth investments; past Permira, ADIA and Lazard experience. Current Heartcore membership is unverified because he is absent from the current published roster.

Published by the manager as a member of the crypto-native investment team at its first Web3 fund close. Current Heartcore membership is unverified because he is absent from the current published roster.

Anne Klüssendorf is published by Heartcore Capital as Accountant.

Bérenger Teboul-Danguin is published by Heartcore Capital as Investor.

Emma Kullenberg is published by Heartcore Capital as Office Assistant.

Gustav Dalby Hillmann is published by Heartcore Capital as Finance Assistant.

Heidi Haurholm-Rasmussen is published by Heartcore Capital as Partner and Head of Capital Formation.

Ishita Sinha is published by Heartcore Capital as Events and Communications Associate.

Johan-Emil Pind is published by Heartcore Capital as Investor Relations Assistant.

Lærke Rud Hansen is published by Heartcore Capital as Investor.

Magnus Melau is published by Heartcore Capital as Finance & ESG Manager.

Malte Hjortkjær is published by Heartcore Capital as Legal Assistant.

Max Niederhofer is published by Heartcore Capital as Partner.

Michael Baczyk is published by Heartcore Capital as Investor.

Mikkel Louekari Randsborg is published by Heartcore Capital as Head of Transactions.

Naza Metghalchi is published by Heartcore Capital as Partner.

Péter Szalay is published by Heartcore Capital as Finance Assistant.

Saina Gheshlagh Larsen is published by Heartcore Capital as Head of Compliance and Risk Management.

Signe Kaae Veistrup is published by Heartcore Capital as Legal Assistant.

Signe Marie Sveinbjørnsson is published by Heartcore Capital as Partner & COO.

Tomáš Fanta is an Investor at Heartcore Capital and joined its Web3 team in2025. His background includes crypto investing at RockawayX, investment banking in M&A and credit markets, and corporate finance and valuation at Berkeley Research Group.

Yacine Ghalim is a Partner at Heartcore Capital and a member of its Web3 investment team. He joined the firm in2013 and previously worked in proprietary trading at Goldman Sachs; his personal early crypto investments are not assumed to be manager fund investments.

Christian Lindegaard Jepsen is published by Heartcore Capital as Partner.

Jimmy Fussing Nielsen is published by Heartcore Capital as Partner & CEO.

Davide Vacondio is Analyst at M Ventures. Biotechnology analyst who joined as a fellow in2025. Has Modena biology degree, Trieste neuroscience MSc and VrijeUniversiteitAmsterdam neuroscience PhD researching Alzheimer’s neuroinflammation and blood-brain-barrier dysfunction. Previously scientific lead for EQT LifeSciences’ dementia fund with AmsterdamUMC.

Eyal Ben Ami is Associate - Scientific Lead at M Ventures. Biotechnology scientific lead who joined2022 after MOYABio scientific leadership and development work at BiolineRx/ImmunoBrain. Holds Technion neuroimmunology PhD, HebrewUniversity biotechnology MSc and TelAviv executive MBA; completed Paris research fellowship.

Isabell Hammann is Assistant at M Ventures. Assistant who joined2022 after eight years as Merck M&A executive assistant and earlier executive-support roles. Has LondonSouthBank international-business master’s and Lincoln European-business degree.

Leonie Willemse is Assistant at M Ventures. Assistant whose own biography specifies executive support to a managing director. Previously office/team manager for an international university and thirteen years at EpsonEurope coordinating secretarial work and travel.

Maxim Kolesnikov is Analyst at M Ventures. Biotechnology analyst who joined as a fellow in2025. Has BritishColumbia microbiology/immunology degrees and Basel structural-biology/biochemistry PhD. Co-developed an early biotech project through NucleateActivator and proof-of-concept work.

Oliver Lyth is Associate at M Ventures. Biotechnology associate who joined2024 after LifeArc venture diligence and IPGroup life-sciences investing. Oxford biochemistry graduate with ImperialCollege molecular-parasitology PhD studying malaria red-cell infection.

Robert Even is Business Development Manager at M Ventures. Israel business-development manager for electronics and sustainability since2019. Experience spans 3Dprinting, nanotechnology and opticalinspection startups. Holds INSEAD MBA and studied McGill mechanicalengineering.

Sarah Luppino is Principal at M Ventures. Technology principal focused on frontier technology, sustainability and electronics; joined2021 after Mars&Co strategy consulting and startup work. MIT organic-chemistry doctorate investigated semiconductor materials.

Bauke Anninga is Executive Director at M Ventures. Biotechnology investor who joined2019 after healthcare investment banking at Jefferies and life-sciences diligence work. Co-founded InnovationForum; holds King’s College London cancer-studies PhD and Twente technical-medicine MSc. Current directory says ExecutiveDirector despite older narrative InvestmentDirector.

Björn Kuhl is Principal at M Ventures. Biotech principal who joined2021 after Merck strategy consulting, Sandoz portfolio/business development and IMS/IQVIA consulting. Holds McGill experimental-medicine PhD, London biomedical-sciences MSc and Lübeck molecular-biotechnology BSc; conducted RagonInstitute immunology/virology research.

Caroline Soulard is Chief Financial Officer at M Ventures. Finance leader who previously spent five years evaluating corporate acquisitions, divestments and strategic projects at Merck. Participated in its GoGlobalFinance programme and studied economics/finance at Bocconi and Manchester.

Christian Patze is Executive Director at M Ventures. Technology investor specialising in electronics, frontier technology and sustainability. Joined2016 after Merck consulting and AirLiquide strategic marketing. Chemistry doctorate research addressed OLED materials; holds a Collège des Ingénieurs MBA.

Christian Uhrich is Executive Director at M Ventures. Joined2019 after Merck strategic consulting, Accenture and Seeburger digital-transformation work. Has Mannheim MBA and Karlsruhe business-informatics diploma. Current directory identifies ExecutiveDirector; older biography narrative retains InvestmentDirector.

Ebru Uzun is Head of Business Operations at M Ventures. Business-operations leader with pharmaceutical consulting and MilliporeSigma bioprocessing/CDMO leadership experience. Previously entrepreneur-in-residence at the venture unit. Holds a Hult MBA and UCL clinical-neuroscience MSc.

Isabel Klein is Principal at M Ventures. Technology principal who joined2025 after investing in hard technology at RhapsodyVenturePartners. Caltech PhD research studied ultrafast semiconductor photophysics; based inBoston.

Javier Rodriguez is Head Technology Investments at M Ventures. Leads technology investment since2025, following service as venture CFO from2016. Earlier Merck corporate-controlling work began2015 and specialty-chemicals experience includes ICI and Givaudan. Holds a Maastricht corporate-finance master’s and Davidson economics degree.

Noga Yerushalmi is Investment Director at M Ventures. Leads the Israel Bioincubator and biotechnology investing. Joined2017 after discovery/R&D and venture-development work at Zetiq, RosettaGenomics, miCure and FutuRx. TelAvivUniversity graduate with NIH postdoctoral training; represents Merck on AIONLabs investment committee.

Oliver Hardick is Investment Director at M Ventures. Life-science tools and manufacturing investor. Founded Puridify in2013 from UCL engineering-doctorate research, leading its financing and2017 acquisition by GEHealthcare. Own biography also describes entrepreneur-in-residence work; current directory title is InvestmentDirector.

Sebastian Schöfer is Investment Director at M Ventures. Technology investor who joined2017 after High-Tech Gründerfonds portfolio management and Cambridge solar-technology startup commercialisation. Has a Cambridge physics PhD and UniversityofTexasatAustin physics master’s.

Vijay Narasimhan is Director of Technology Investments and Partnerships at M Ventures. Joined2026 to lead technology investments and partnerships following EMD Electronics research-collaboration leadership. Experience covers AI/materials research. Holds Ottawa computer-engineering degree, Cambridge nanotechnology master’s, Stanford materials-science doctorate and IE/Brown MBA.

Damgaard Company is a Danish privately owned investment company and active venture/growth investor focused on B2B software and B2C technology platforms. Its own historical account dates the investment brand to 2003, after Preben Damgaard’s software entrepreneurship and Microsoft executive work; the underlying legal A/S entity was created in 2000, a distinct incorporation date. The active legal entity is DAMGAARD COMPANY A/S, Danish CVR 25538315 and LEI 529900WO0SB3MQYKJW30, based in Holte. Current own leadership is Group CEO Lars Romedahl and board chair Charlotte Damgaard, with Jørgen Kjergaard Madsen and Katrine Damgaard on the published board. Founder Preben Damgaard died in 2022 and is retained as a historical founder rather than a current executive. The company provides funding, board participation, operational support and management coaching; it seeks demonstrated commercial traction and primarily invests in established software growth businesses. Its own portfolio confirms a 2016 investment in Configit’s manufacturing configuration technology alongside Polaris Private Equity IV, while the issuer owner separately audits the exact May2016 transaction and undisclosed allocation. Other source-qualified technology portfolio includes Templafy, Dixa and historical AI document-processing company Paperflow, acquired by Boyum IT Solutions in 2022. Current and exited holdings are distinguished: OrderYOYO exit2025, Saxo exit2023 and earlier acquisitions are not represented as new issuer cash. No direct neuroscience strategy or neuroscience investment is established by these public sources. Damgaard is a private principal investment company; no external LP fund vehicle, actual LP close or committed fund capital has been verified, and registered share capital/private balance-sheet assets are not substituted as a venture fund. It remains distinct from Damgaard Group, the Charlotte & Preben Damgaard Foundation, Erik Damgaard’s separate ventures, and its individual founder’s personal investments.

Co-founded Canaan as a spin-out of GE Venture Capital and helped develop its technology investment practice. Canaan publishes this as a memorial profile with tenure 1987–2021.

Life-sciences investor with experience in biotechnology strategy, business development, operations and company incubation.

Leads Canaan’s fintech practice, investing in financial infrastructure, platforms and technology-enabled financial products.

Supports technology companies with experience building revenue, marketing and strategic partnerships at American Express, PayPal and Stripe.

Technology investor focused on marketplaces, aerospace and enterprise software, with earlier experience in telecommunications and startup operations.

Technology investor and former machine-learning engineer whose career includes defense products and scaled financial-services software.

Leads global capital formation for Canaan following investor-relations and business-development work at Foundation Capital.

Invests with Canaan’s fintech and consumer teams, drawing on operating experience at the financial platform Public.

Operating partner who assists Canaan portfolio companies with commercial execution, drawing on prior chief revenue officer experience.

Healthcare analyst with experience supporting venture firms and serving as a human-resources director at venture-backed technology companies.

Venture investor supporting consumer and enterprise technology businesses, with earlier startup and private-equity operating experience.

Leads Canaan’s cybersecurity investing, drawing on experience in enterprise technology, cloud infrastructure and security.

Biopharmaceutical investor involved in creating, financing and supporting new therapeutic companies.

Leads investments in enterprise infrastructure software, with experience as a founder and executive in software, cloud infrastructure and AI. Atlantic Bridge’s March22,2025 published directory identifies Kumar Sreekanti as Venture Partner. This is a dated published affiliation; current tenure is not independently confirmed by the redesigned live site. Kumar Sreekanti is a venture partner at Atlantic Bridge Ventures, specializing in software, cloud infrastructure, and AI/ML. With over 30 years of industry experience, Kumar has a proven track record of identifying and investing in cutting-edge technology startups. As a three-time founder-CEO Kumar brings a wealth of operational expertise that is invaluable to founders building and scaling startups. Prior to joining Atlantic Bridge, Kumar served as the Global CTO and Head of Software at Hewlett Packard Enterprise (HPE), where he led the innovation agenda and technology roadmap for the HPE software-defined portfolio. He joined HPE through the acquisition of BlueData, where he was the founder and CEO. Before that, Kumar held leadership roles in R&D at top technology companies such as VMware, Akamai, and Adaptec. Kumar is a graduate of the Indian Institute of Technology, Kanpur. In his free time, he enjoys gardening, photography, running, and delving into philosophy.

Consumer-technology investor with a background in strategy, operations, sales and marketing.

Drug-development executive whose work spans discovery through regulatory approval, particularly oncology and genetic diseases.

Technology investor focused on ecommerce and enterprise/cloud businesses, including experience backing social gaming and luxury resale.

Biotechnology and pharmaceutical executive experienced in platform innovation and drug development, formerly leading oncology discovery at Bristol Myers Squibb.

Invests in biopharmaceutical companies addressing unmet therapeutic needs and supports women entrepreneurs and investors through Canaan’s Women of Venture program.

Drug-development executive experienced in translating research into medicines, including work in HIV, respiratory disease and diabetes.

Former operating executive who invests in artificial intelligence, robotics, marketplaces and real-estate technology.

Physician and biotechnology operating executive who helps create and develop therapeutic companies, formerly CEO of CuraGen.

Life-sciences investor with experience connecting research institutions and biotechnology companies; formerly led emerging-science and innovation work at Pfizer.

Hyun Tae Kim, also styled Kim Hyun Tae in the manager’s legacy English roster, was a generalmanager and bio-investment leader at SouthKorea’s MiraeAssetCapital. Acticor’s2018 funding announcement and2021 regulator-approved registration independently identify him as its boardobserver representing the Koreaninvestor. The2021biography reports that he joinedMirae in2017, following nineyears of pharma/biotechnology/medicaldevice equityresearch and fouryears in pharmaceutical licensing/development. It lists a BachelorofScience fromtheUniversityofCalifornia,Davis, and aMasterofScience fromKAIST (KoreaAdvancedInstituteofScienceandTechnology). The affiliation is historical; he is absent fromthecurrent2026directory and no currentmanagerrole is asserted. No independentlymatched originalportrait was found; he is distinct from currentMJ Kim and otherKim homonyms.

Jason Lee is identified in Mirae Asset Capital’s current public investment roster as TMT Investment Team — Manager. Published investment interests: AI, Applications, Consumer. Prior organizations named in the official profile include Hanwha Investment & Securities. The profile lists education in Emory University, Goizueta Business School. This manager-specific identity is distinct from homonymous existing professionals at other organizations.

Jinwoo Lee is identified in Mirae Asset Capital’s current public investment roster as TMT Investment Team — Sr. Manager. Published investment interests: AI, Cloud/Infra, Space/Defense Tech. Prior organizations named in the official profile include Sparklab Ventures, IBM. The profile lists education in Northwestern Kellogg MBA, University of Illionis Urbana Champaign B.S in Industrial Engineering. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Bob Cha is identified in Mirae Asset Capital’s current public investment roster as TMT Investment Team — Team Lead. Published investment interests: Consumer & Enterprise Tech. Prior organizations named in the official profile include NAVER, Korea Investment Partners. The profile lists education in B.A in Philosophy from Peking University. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Paul Lee is identified in Mirae Asset Capital’s current public investment roster as Investment Team 1 — Manager. Published investment interests: Robotics, Space Tech. The profile lists education in Seoul National University Business & Computer Science. This manager-specific identity is distinct from homonymous existing professionals at other organizations.

Jun Won Kim is identified in Mirae Asset Capital’s current public investment roster as Investment Team 2 — Manager. Published investment interests: Deep Tech, AI Infra, Emerging Markets. The profile lists education in University of Southern California, Business Administration. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Soojin Lee is identified in Mirae Asset Capital’s current public investment roster as Investment Team 2 — Sr. Manager. Published investment interests: AI, Deep Tech, Consumer. Prior organizations named in the official profile include KPMG. The profile lists education in University of Cambridge, Masters in Mechanical Engineering (MEng). The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Songhwa Choi is identified in Mirae Asset Capital’s current public investment roster as BIO Investment Team — Sr. Manager. Published investment interests: Novel Therapeutics Platform, , Digital Therapeutics/Healthcare. Prior organizations named in the official profile include Hanmi Pharmaceuticals. The profile lists education in Stony Brook University, Ph.D. in Molecular and Cellular Biology; Seoul National University, Master of Pharmacy; Seoul National University, Bachelor of Pharmacy. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Daniel Kwon is identified in Mirae Asset Capital’s current public investment roster as BIO Investment Team — Team Lead. Published investment interests: Bio/Healthcare. Prior organizations named in the official profile include Samsung Venture Investment, Bio Investment, LG Chem Life Sciences, Business Development, Daewoong Pharmaceuticals, Global Stratey. The profile lists education in Kyunghee University, Master of Pharmacy; Kyunghee University, Bachelor of Pharmacy. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

MJ Kim is identified in Mirae Asset Capital’s current public investment roster as BIO Investment Team — Sr. Manager. Published investment interests: Bio/Healthcare. Prior organizations named in the official profile include SCAI Therapeutics, Institute for Basic Science, Tokyo Institute of Technology. The profile lists education in PhD, KAIST Chemistry; BSc, KAIST Chemistry. This manager-specific identity is distinct from homonymous existing professionals at other organizations.

Jeongyeob Jay Park is identified in Mirae Asset Capital’s current public investment roster as Investment Team 3 — Sr. Manager. Published investment interests: Contents, Consumer, AI, Space Tech. Prior organizations named in the official profile include Mirae Asset Securities. The profile lists education in Sogang University, Bachelor of Business Administration. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Jonathan Hwang is identified in Mirae Asset Capital’s current public investment roster as Investment Team 1 — Director. Published investment interests: Deep Tech, Semiconductor, Robotics, VR/AR. Prior organizations named in the official profile include Mirae Asset Securities, Samsung Electronics. The profile lists education in POSTECH, M.S. & B.S. Electrical and Computer Engineering. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Sangjoon Park is identified in Mirae Asset Capital’s current public investment roster as Investment Team 1 — Sr. Manager. Published investment interests: Deep Tech, Energy, Battery, AI, Space. Prior organizations named in the official profile include AIP Patent & Law Firm, BAE, KIM & LEE IP. The profile lists education in Seoul National University Material Science & Engineering. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Hyojeong Kim is identified in Mirae Asset Capital’s current public investment roster as Investment Team 3 — Team Lead. Published investment interests: AI/Medtech, Digital Healthcare, Medical Platform, Beauty. Prior organizations named in the official profile include J & J Commercial lead. The profile lists education in Seoul National University, Bachelor of Pharmacy. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Jay Chung is identified in Mirae Asset Capital’s current public investment roster as Investment Team 1 — Team Lead. Published investment interests: ICT. Prior organizations named in the official profile include Mirae Asset Securities, Mirae Asset Securities (USA), Mirae Asset Securities & Investments (USA). The profile lists education in University of Michigan B.S in Computer Science. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Kil young Lee is identified in Mirae Asset Capital’s current public investment roster as Investment Team 2 — Team Lead. Published investment interests: ICT. Prior organizations named in the official profile include Mirae Asset Securities. The profile lists education in Fudan University, MBA ; Sogang University, Bachelor of Chinese Culture & Economics; CFA (Charterd Financial Analyst). The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Hansoo Kim is identified in Mirae Asset Capital’s current public investment roster as New Growth Investment Dept. 2 — Managing Director. Published investment interests: Life Sciences/Health Care, Diagnostics. Prior organizations named in the official profile include LG Chemical (Life Sciences), LG Household & Healthcare, CrystalGenomics. The profile lists education in Seoul National University, Master of Pharmacy; Seoul National University, Bachelor of Pharmacy. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Choong Hwan Lee is identified in Mirae Asset Capital’s current public investment roster as New Growth Investment Dept. 1 — Managing Director. Published investment interests: ICT. Prior organizations named in the official profile include Mirae Asset Securities, Mirae Asset Global Investments. The profile lists education in Seoul National University. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Ji Kwang Chung is identified in Mirae Asset Capital’s current public investment roster as CEO. The individual’s original named-card portrait and biography fields are independently sourced; no personal cash participation is inferred.

Kenjiro Watanabe is published in Mitsui Global Investment’s current public team. Kenjiro, also published as Ken Watanabe, joined MGI as President and CEO in June 2026 and is co-managing partner of E12 Ventures. His own biography describes leadership of private equity and capital-solutions businesses at Mitsui & Co., earlier venture work in Beijing and cross-border M&A. He holds a Waseda science and engineering master’s degree and a Peking University executive MBA.

Makiko Kikuchi is published in Mitsui Global Investment’s current public team. Makiko joined MGI in August 2022 and works in the administration team. After studying law at Kyoto University, she worked in the accounting department of Mitsui & Co.’s IT and Communication Business Unit. Her biography records a move to Silicon Valley in 2013.

Irene Mingozzi is published in Mitsui Global Investment’s current public team. Irene’s current directory labels her Venture Partner, while her own biography describes Investment Principal at MGI and E12 Ventures. Both published descriptions are retained without guessing a transition. Her background includes founding a company, running an accelerator and directing a San Francisco innovation hub, followed by venture-investment sourcing and execution.

Toshihiro Terada is published in Mitsui Global Investment’s current public team. Toshihiro joined MGI as principal in June 2024 and focuses on climate technology. His own biography describes more than a decade at Mitsui & Co. across consumer products, chemical materials, private equity and corporate finance. He studied business and commerce at Keio University and previously lived in Vietnam.

Kazufumi Nakamura is published in Mitsui Global Investment’s current public team. Kazufumi invests in biotechnology and life sciences, with an interest in genetics and genomics. His own biography describes biotechnology company creation, business development and scientific evaluation at Santen, and clinical development at Janssen including Alzheimer’s programmes. He holds a pharmaceutical-science degree from Tokyo University of Science and is licensed as a pharmacist in Japan.

Yukitaka Kojima is published in Mitsui Global Investment’s current public team. Yukitaka focuses on healthcare AI. His own biography identifies investment work involving Stately Bio, Leash Bio, Ellipsis Health and Rhino FCP, and support for RallyBio, Bionova, Ensem and Neura Health. Previously he managed investments at Mitsui & Co. and worked in corporate insurance, commodity derivatives and private equity. He studied economics at the University of Tokyo and holds the CFA designation.

Paulina Szyzdek is published in Mitsui Global Investment’s current public team. Paulina’s own MGI biography identifies a principal role supporting E12 Ventures investments in deep technology, industrial markets and frontier technologies. It describes earlier investing affiliations including Bosch Ventures and banking/consulting work at State Street, Euroclear, Deutsche Bank and Chatham Financial. Her degrees include finance, disruptive innovation and an MBA. Her E12 team function is qualified rather than automatically treated as a direct MGI cash buyer.

Caroline Pinkney is published in Mitsui Global Investment’s current public team. Caroline has worked at MGI since 2010, supporting investment research and sourcing, technical platforms and the firm’s online presence. Her biography identifies digital health as an investment interest. Before MGI she interpreted for NUMMI’s Toyota and General Motors teams and worked at Intel Museum. She studied Japanese and Spanish at Stanford.

Masaya Watanabe is published in Mitsui Global Investment’s current public team. Masaya joined MGI from Mitsui & Co. in December 2025 and focuses on biotechnology, healthcare and emerging sectors. He began working in the parent’s Corporate Development Business Unit in 2023, including private-equity and venture-fund portfolio management. He holds a master’s degree in life sciences from the University of Tokyo. The own directory does not state a formal job title.

Orie Schneider is published in Mitsui Global Investment’s current public team. Orie joined the Silicon Valley office’s opening staff in late 2004. Her biography describes executive and administrative support, human-resources work and accounting responsibilities added from 2013. She previously worked in customer service at a Japanese commercial bank.

Indri Ongko is published in Mitsui Global Investment’s current public team. Indri oversees finance, accounting, investment-fund operations and reporting. Her published biography describes earlier venture capital finance leadership, more than 15 years in venture-debt finance and a public-accounting background. She studied accounting at the University of Texas at Austin and is a California and Texas CPA.

Loleta Robinson is published in Mitsui Global Investment’s current public team. Loleta is a physician entrepreneur and President and CEO of Fortis Industries. Her own biography describes work at Thermo Electron and MedImmune Vaccines, entrepreneur-in-residence roles at Blue Cross Blue Shield Nebraska and NIH SEED, an MD from Kansas, and an MBA from Colorado Denver.

Reiko Namikawa is published in Mitsui Global Investment’s current public team. An MD and PhD trained at Nagoya University, Reiko began her U.S. research career in Irving Weissman’s Stanford laboratory and was a founding scientist at SyStemix. Her own biography describes senior biotechnology roles and technology-adviser work with MGI since 2011.

Ellen Sheets is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation SeQure DX, Founding CEO. Further career details and exact affiliation dates are not published in this source.

Pauline Jen Ryan is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Biotech Executive. Further career details and exact affiliation dates are not published in this source.

John Ripple is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Brave Bio, Board of Directors. Further career details and exact affiliation dates are not published in this source.

Niranjana Nagarajan is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Crosstalk Bio, Founding CEO. Further career details and exact affiliation dates are not published in this source.

Robert Millman is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Ncontrol Therapeutics, Founding CEO CoStim, Co-Founder, President (Acquired by Novartis). Further career details and exact affiliation dates are not published in this source.

Spiros Jamas is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Biotech Entrepreneur. Further career details and exact affiliation dates are not published in this source.

Barbara Fox is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Tilos Therapeutics, Founding CEO (Acquired by Merck). Further career details and exact affiliation dates are not published in this source.

Dave Hava is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Biotech Executive. Further career details and exact affiliation dates are not published in this source.

David de Graaf is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Mediar Therapeutics, Board of Directors. Further career details and exact affiliation dates are not published in this source.

Adrian Ray is published by Mass General Brigham Ventures as Entrepreneur in Residence. The same source identifies the professional designation Biotech Executive. Further career details and exact affiliation dates are not published in this source.

Jessica Ballinger is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation Biotech Executive. Further career details and exact affiliation dates are not published in this source.

Cecilia Fernández is published by Mass General Brigham Ventures as Entrepreneur in Residence. The same source identifies the professional designation Biotech Executive. Further career details and exact affiliation dates are not published in this source.

Jonathan Levinson is published by Mass General Brigham Ventures as Entrepreneur in Residence. The same source identifies the professional designation Biotech Executive. Further career details and exact affiliation dates are not published in this source.

Thomas (Tom) Backus is a Venture Associate at Mass General Brigham Ventures. His primary biography describes work across preclinical development, pharmaceutical strategy and technology commercialization. It also identifies him as a commercial lead for the related Amplify translational program; that programme affiliation does not establish a separate LP fund.

Bhamini Vaidialingam is a Venture Associate at Mass General Brigham Ventures. The current primary biography describes a scientist with approximately a decade of experience in the pharmaceutical and biotechnology industries, including company formation. This published designation establishes her manager affiliation; exact employment dates are unspecified.

Sergine Brutus Sweeney is published by Mass General Brigham Ventures as Venture Associate. Further career details and exact affiliation dates are not published in this source.

Stacey Brenner leads investor relations and finance as a Senior Director at Mass General Brigham Ventures. She has more than25years of venture-capital and private-equity experience. Her primary biography identifies earlier fundraising work at Flagship and MPM and previous positions with Morgan Stanley and Cambridge Associates.

Julius (Jay) Knowles is a Partner at Mass General Brigham Ventures. His primary biography describes more than25years of life-sciences business development and company building. Published director affiliations include Keros, Modal,65Therapeutics and20Bio; the same source lists observer relationships at Abcuro, Kesmalea, Klear and Photys.

Carl Berke is a Partner at Mass General Brigham Ventures. His career spans more than three decades of helping bring scientific innovations into commercial use. The current primary biography names director affiliations at InStride Health, Tuesday Health, Pykus Therapeutics, PreDICTA and Walden BioSciences. Those institutional board roles do not establish personal cash investments.

Roger Kitterman helped establish Mass General Brigham Ventures in2008 and is its Managing Partner. His current published title also includes Senior Vice President for Venture, Business Development and Licensing. His work spans forming, sourcing, financing and developing the investment portfolio; assets under management described in his older biography are distinct from closed fund capital.

Self-published finance and operations associate at2degrees. His professional profile identifies Davidson College studies during2017–2021 and previous Bend,Oregon experience, corroborating the exact named Davidson university portrait and dated2019 athletics record. The photograph is a genuine historical university image, not a current corporate headshot.

Published by2degrees’ public professional directory as an affiliated team member. The accessible primary directory does not state her precise functional title, educational background, employment start date or a verifiable individual portrait; those details are left unspecified.

Self-described operator and investor working with early-stage technology, publicly affiliated with2degrees. His own professional profile publishes Copenhagen Business School studies in finance, governance and strategy, and earlier Global Mindpool involvement; current exact investment rank and credential details are not disclosed by the accessible primary profile.

Executive director of Two Degrees ApS named in its audited2025 report approvedJuly2026. His public professional profile describes family-office and impact-investing work and publishes Aarhus School of Business studies; exact credentials and their award dates are not specified here.

Registered executive director of Two Degrees ApS in its audited2025 report approved8July2026, contributing to the company’s investment and holding-company governance. The primary company filing does not publish detailed education or a verified individual professional portrait.

Managing director of Two Degrees ApS in its audited2025 report approvedJuly2026. Co-founded Urban Partners/NREP in2005, served as CEO until2019 and subsequently executive chair; his self-provided2025 Milken biography describes earlier corporate and entrepreneurial work across Copenhagen, London, Boston and Santiago.

2degrees is a Copenhagen-based private investment platform backing early-stage businesses in climate, sustainability and scientific technology, including Kvantify quantum-computing software. Its own site describes a small private investment company, deploying selectively from initial company formation through seed stage across sectors and countries. The legal company Two Degrees ApS, CVR28687729, was established1March2005 and publishes a July2026-approved audited2025 annual report naming Mikkel Bülow-Lehnsby as managing director and Jeppe Bülow-Lehnsby and Steen Sønderby as directors. The public company LinkedIn directory additionally names Soren Wiberg Holm, Ragnar Schmidt and Sabrina Colberg. The profile represents the published investment platform with this source-qualified corporate holding identity; individual deals name the 2degrees brand and do not disclose whether a subsidiary investment vehicle holds each security. It is distinct from quantum VC2xN, the New Zealand telecommunications company and the 2Degrees Investing Initiative. No external LP fund close or portfolio valuation is represented as raised cash.

Agnieszka Ratjczak is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2025-07-01. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Christian Dubarry is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2023-01-01. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Kyeong Je is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2024-12-04. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Marc Pauchard is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2025-07-01. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Melanie Cullins is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2023-11-23. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Melanie Rüther is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2023-11-23. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Pierre Demoitié is a publishedCommunications and Event Manager for Eureka's Belgian Chair2026–27, representingWallonia / SPW EER. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Rudolf Grasveld is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2024-12-04. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Urs Gut is listed as a statutory director of Eureka Network AISBL, Belgian international nonprofit association BE0429.585.680, in the direct Belgian KBO register currentOctober7,2026, with registered appointment2025-07-01. This is an exact legal-register identity. A further published professional biography, authentic individual portrait and any bridge to differently named participants in the network's2026 publication were not independently established; no outside employer or personal cash investment is inferred.

Alexandra Lacroix is a publishedChair Support for Eureka's Belgian Chair2026–27, representingWallonia / SPW EER. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Mohamed Amin Ali is a publishedDeputy National Project Coordinator for Eureka's Belgian Chair2026–27, representingWallonia / SPW EER. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Desiree Simonetti is a publishedPolicy Advisor for Eureka's Belgian Chair2026–27, representingBrussels / Innoviris. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Stéphanie Vieren is a publishedCommunications Manager for Eureka's Belgian Chair2026–27, representingBELSPO. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Fabrice Quertain is a publishedBelgian HLR for the Partnership for Innovative SMEs, Wallonia for Eureka's Belgian Chair2026–27, representingWallonia / SPW EER. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Stijn Maas is a publishedDeputy High Level Representative & National Project Coordinator, Brussels for Eureka's Belgian Chair2026–27, representingBrussels / Innoviris. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Julie Jasmes is a publishedDeputy High Level Representative & National Project Coordinator, Wallonia for Eureka's Belgian Chair2026–27, representingWallonia / SPW EER. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Aziz Naji is a publishedEureka President, BELSPO for Eureka's Belgian Chair2026–27, representingBELSPO. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Pascale Van Dinter is a publishedHigh Level Representative, BELSPO for Eureka's Belgian Chair2026–27, representingBELSPO. Belgium's chair runsJuly1,2026–June30,2027 and coordinates federal/regional innovation collaboration through BELSPO, Innoviris, VLAIO and SPW EER. The official Chair directory supplies the named original portrait. This is a scoped government representative or Chair-support affiliation, distinct from employment by Eureka's Brussels Secretariat; individual investment authority or personal cash checks are not inferred.

Justin Blanchart serves asLegal Advisor & Controller in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Jorge Liz serves asOperations Manager Global Cooperation & Corporate Activities in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Linden Farrer serves asOperations Manager Eurostars in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Catherine Simmons serves asCommunications Manager in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Peter Chisnall serves asDirector Strategy & Business Development in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Alain Van Esse serves asDirector Finance & Administration in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Dirk Matton serves asDirector IT & Digitalisation in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Brit Helle serves asDirector General in Eureka Network AISBL's current public Secretariat management directory. Eureka is a Belgian international nonprofit operating international research/innovation programmes, including Eurostars and EU-funded Innowwide, for SMEs and other research participants. This professional's verified published scope is the named management function in the Brussels Secretariat; the official named directory provides the authentic portrait. Additional career dates, qualifications and personal investment activity are not published in that directory and are not invented.

Eureka Network AISBL is the Belgian international nonprofit association operating the intergovernmental Eureka research and innovation network. Its enterprise number is BE 0429.585.680 and registered office is Avenue de Tervueren 2, 1040 Etterbeek, Brussels. The international initiative began on 17 July 1985; the legal association acquired personality on 21 October 1986. Authentic French notarised statutes and the Belgian KBO register establish continuity from association d'EUREKA to Eureka Network, its current registered name since 6 September 2024. The Secretariat is part of this institution, distinct from unrelated Eureka venture managers and technology companies. The network supports international advanced-technology research and commercialisation by companies, universities and research organisations across 47 countries. Programmes include Eurostars, Innowwide, Eureka Clusters, Network Projects, Globalstars and Investment Readiness. Its AI and life-science relevance includes gMendel's genetic diagnostics project, which the company's 2023 review identifies as Innowwide-supported and completed in November 2023. A Eureka project association alone does not prove that this institution paid every national research grant or bought equity. Innowwide is an EU-funded market-feasibility grant programme administered by Eureka within the European Partnership on Innovative SMEs, rather than a separate company, LP fund or additional cash buyer. Latvia's original September 2022 government publication identifies Association d'Eureka AISBL as coordinator under European Commission grant agreement 101055476, signed on 20 June 2022. Standard support is up to EUR 60,000 for a six-month SME project, with an independent local subcontractor. Programme ceilings and consultant-reported awards remain distinct from actual paid-to-date cash and payment dates. The earlier Horizon 2020 pilot/CDTI consortium is not automatically the provider for a 2022 first-call award. Innovation Fund Denmark explicitly states it does not award Innowwide funding, so the programme is not duplicated as its national Eurostars contribution. The current Secretariat directory names eight managers. Its approximate 40 employees are not inferred as a full named roster. The sixteen published Belgian Chair 2026–27 people are separately scoped external representatives or support from BELSPO, Innoviris, VLAIO and SPW EER. Belgium's chair runs from 1 July 2026 to 30 June 2027, with Aziz Naji as published President. Former Swiss President Marc Pauchard is not represented as current President, although the October 2026 KBO register separately retains his statutory directorship. Brit Helle's daily-management appointment is 1 September 2021; migrated 2025 news timestamps are not appointment dates. The direct legal register supplies nine statutory directors. Differences between registry names Urs Gut, Rudolf Grasveld, Kyeong Je and Agnieszka Ratjczak and published board names Andreas Gut, Dolf Grasveld, Yeon Woo Choi and Agnieszka Ratajczak remain qualified without unsupported person merges. The official logo and 24 named current Secretariat/Belgian Chair portraits were visually verified. Eight statutory-only people have unresolved authentic-portrait and expanded-biography gaps. EU co-funding, membership contributions, grant envelopes and network-wide investment totals are institutional resources, rather than AUM, LP fund closes or newly paid company rounds.

ReMoni is the Danish AI and sensing technology company REMONI A/S, identified by its own website as CVR35212124, based in Skanderborg. It combines patented non-invasive clamp-on sensors with statistical models and artificial intelligence to monitor electricity, heating, cooling and water and optimize resource use in buildings and industrial systems. Products include Predictive Heat Optimization, EnergyXplorer and monitoring/control platforms; its research includes power-quality analysis, district heating and digital twins. The company website describes operational founding in2014, while the historical investor article says2013; this discrepancy is not resolved into an exact legal incorporation date. Its contact page separately identifies ReMoni Danmark A/S CVR39326345 and Romanian ReMoni Technologies RO S.R.L.; those operating entities are distinguished from this company profile. The public directory publishes leadership, commercial staff and three directors with authentic named photographs, but has conflicting leadership layouts: Anders Hjortsholm is listed as CCO while another block calls Anders Steen Mortensen CCO rather than Head of Building Optimization. Both published affiliations are retained with that uncertainty, without invented tenure dates. Capnova was a historical shareholder and announced its exit in2020 alongside Kenneth Iversen's reported DKK20M investment; the source does not separate secondary acquisition proceeds from new issuer cash. A September2020 announcement distinguishes an EUR480,000 Innobooster award from Kenneth's prospective EUR1,350,000 matching private investment; grant disbursement and completion of the matching investment are not established. CORDIS separately records REMONI A/S as a beneficiary of grant958600 with EUR637,087.50 net EU contribution, not the entire consortium's EUR1,708,193.75 grant or EUR2,239,943.75 project cost. Awards, future commitments and those aggregate budgets are not recorded as completed equity cash.

Anders Hjortsholm is listed in ReMoni's own public professional directory as Published CCO affiliation; conflicting current leadership blocks. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Anders Steen Mortensen is listed in ReMoni's own public professional directory as Commercial leadership and building optimization; title conflict. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Anders Thostrup is listed in ReMoni's own public professional directory as Senior Consultant. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Anne Ginderskov Hansen is listed in ReMoni's own public professional directory as Board Member. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Bo Eskerod Madsen is ReMoni's published CEO and founder and a member of its board. His own company biography describes a career taking R&D into market-ready products and doctoral/statistical data-analysis studies connected to Aarhus University and the University of Auckland. He founded ReMoni to combine easier-to-install sensors with data science and AI for resource monitoring and optimization. The company directory supplies this genuine named portrait. Operational founding-year statements differ between the company and its historical investor and are qualified on the company profile.

Jakob Farver-Vestergaard is listed in ReMoni's own public professional directory as CFO. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Jakob Schytte Nymann Jørgensen is listed in ReMoni's own public professional directory as Software Department Manager. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Kenneth Iversen is ReMoni's published board chairman and an identified shareholder. His company biography describes more than30 years as CEO of Unimerco, where he developed an international industrial business. The historical Capnova announcement reports his DKK20M investment when Capnova exited; the source does not distinguish secondary purchase from new issuer cash. ReMoni separately announced prospective matching private investment for a2020 ultrasound-metering project. No unspecified private investment vehicle or completed matching payment is inferred. This is the genuine named company portrait.

Peter Blauenfeldt is listed in ReMoni's own public professional directory as Senior Business Developer. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Rasmus Møldrup Ladegaard is listed in ReMoni's own public professional directory as Hardware Department Manager. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

Thea Raunsbæk is listed in ReMoni's own public professional directory as Sales Consultant. ReMoni develops AI-based clamp-on sensing and resource optimization technology in Denmark. This photograph is the genuine publisher image attached to the person's named card. The directory does not establish an exact appointment date or a longer career history.

David Nedergaard is published as a Configit product manager leading a development team on Virtual Tabulation-based configuration products. His career spans software development, marketing and media, bringing a technical and commercial perspective. The own2026 summit is dated affiliation evidence; it does not disclose his exact appointment day.

Sigrún Ívarsdóttir is a Configit product manager working on its core technology and product performance with customers and engineers. Her engineering-management master’s degree at the Technical University of Denmark included a thesis on configuration systems. The own2026 summit confirms this public role without an exact appointment day.

Laura Beckwith directs product work at Configit and has worked with its customers since 2010. Her research background concerns software tools for non-programmers. The 2026 summit biography names Oregon State University for her computer-science doctorate, whereas the March2026 own blog biography names University of Washington; institution identity remains source-qualified rather than guessed.

Marc Weinhold is published by Configit as VP Global Sales. Joined Configit in 2017. More than 20 years of experience in Sales of business critical software solutions and services in the field of configuration and ERP. Exact joining days are unverified unless separately sourced.

Shahid Ayub is published by Configit as SVP Global KAM. Joined Configit in 2009. MSc, Electrical Engineering, Technical University of Denmark. 15 years of experience in selling of technical software. Exact joining days are unverified unless separately sourced.

Thomas Randrup is published by Configit as EVP Global Sales Engineering. Joined Configit in 2014. PhD in Mathematics from DTU & Maersk (Industrial Research Fellow). Diploma in Managing IT Software and Service Strategically from SIMI. 16 years of experience in the configuration industry as co-founder of 3Dfacto. Exact joining days are unverified unless separately sourced.

Henrik Hulgaard is published by Configit as VP Product Management. Co-founder of Configit. Holds a PhD in Computer Science from the University of Washington. Associate Professor of Computer Science. Published more than 25 international articles. Exact joining days are unverified unless separately sourced.

Henrik Reif Andersen is published by Configit as Chief Strategy Officer, CSO. Co-founder of Configit. PhD in Computer Science from the University of Aarhus. 25 years' experience in IT development and research. Professor of Computer Science. Exact joining days are unverified unless separately sourced.

Kenneth Hune Petersen is published by Configit as Chief Commercial Officer, CCO. Joined Configit in 2024. Holds a Master of Economic (cand. polit.) from The University of Copenhagen. Extensive experience leading and growing commercial teams in the Americas, EMEA, and APAC at industry leading companies such as SimCorp, Sonion and Milestone Systems. Exact joining days are unverified unless separately sourced.

Damantha Boteju is published by Configit as Chief Product and Technology Officer, CPTO. Joined Configit in March 2023. Over 25 years' experience in software development focusing on enterprise class products. Exact joining days are unverified unless separately sourced.

Lene Linde is published by Configit as Chief Human Resources Officer, CHRO. Joined Configit in 2017. Over 25 years in working with HR and leadership in international growth companies, including engineering, software and IT. Exact joining days are unverified unless separately sourced.

Torben Jespersen is published by Configit as Chief Operating Officer, COO. Joined Configit in 2018. Holds a Master´s Degree in Business Administration from Copenhagen Business School. More than 20 years' experience within Consulting and Consulting Management. Exact joining days are unverified unless separately sourced.

Anne Dorthe Gyldenkærne is published by Configit as Chief Marketing Officer, CMO. Joined Configit in 2020. The Chartered Institute of Marketing Degree, Oxford. Master of Science (MSc) in Public Administration (cand. scient. adm.). More than 20 years' experience in the B2B software marketing space working in international growth companies. Exact joining days are unverified unless separately sourced.

Alessio Ciulli chairs TRIMTECH’s scientific advisory board. His Dundee research focuses on targeted protein degradation, including VHL-binding ligands and PROTAC ternary-complex structures. He co-founded Amphista Therapeutics and leads Dundee’s Centre for Targeted Protein Degradation.

William (Will) McEwan is an academic co-founder and chief scientific adviser at TRIMTECH. He leads a UK Dementia Research Institute group at Cambridge exploring antiviral mechanisms and protein aggregation in neurodegenerative disease. The company identifies his research alongside Leo James’s as a foundation for its TRIM21 platform.

Anders Tang Christensen is published by Configit as Chief Financial Officer, CFO. Joined Configit in 2016. Over 30 years in finance with more than 17 years of experience in financial and operational leadership of high growth software companies. Exact joining days are unverified unless separately sourced.

Johan Salenstedt is published by Configit as Chief Executive Officer, CEO. Joined Configit in September 2019. Over 30 years of experience in executive leadership positions in high growth software companies such as IBM, Adobe and Qlik. Exact joining days are unverified unless separately sourced.

Configit A/S is a Danish enterprise software company founded in 2000 by computer-science researchers Henrik Reif Andersen and Henrik Hulgaard, based on work associated with the IT University of Copenhagen and Technical University of Denmark. Its current primary contact page identifies the operating company as CVR25331532 at Midtermolen3,2100Copenhagen. International offices include separately named US, UK and German entities; these subsidiaries and the holding company are not merged into fabricated legal aliases. Its deep-technology foundation is Virtual Tabulation®, a patented compilation-based method for representing and validating product configurations. Configuration Lifecycle Management connects product rules and data across engineering, sales, manufacture and service, integrating with PLM, ERP and CPQ systems. Configit Ace supplies a shared configuration engine, Configit Quote supports complex sales quoting, and the current Ace Prompt product adds natural-language/AI access to governed product information. The own timeline reports the GenAI product launch in2025. Technical eligibility is grounded in its configuration-logic research and current explicit AI product, not a generic assertion that every configuration algorithm is an AI model. The company’s zero-error/speed/productivity claims remain vendor claims, without independent validation. The live public directory names twelve unique leadership/founder/sales people; Kenneth Hune Petersen’s repeated card is one individual. Johan Salenstedt is the current CEO, and founders Andersen and Hulgaard are currently CSO and VPProductManagement rather than stale CEO/CTO titles from2016. Laura Beckwith is additionally confirmed in current2026 programme and author material as product director, alongside product managers Sigrún Ívarsdóttir and David Nedergaard; fifteen unique public staff/founder profiles are included. Her own2026 sources disagree on her doctorate’s institution, which remains explicitly qualified. Exact role days are unknown except separately proved appointments. Private staff are not invented from aggregate headcounts. CAPNOVA’s own history confirms investment in2001 and disposal in2012, without a ticket or exact day. Its DKK73M figure describes Configit’s2017 gross profit, not financing or an investor exit return. Polaris Private Equity acquired65% of shares onFebruary4,2016, price undisclosed: this is a majority-share transaction, not an asserted cash raise of the same value. DamgaardCompany subsequently invested capital and management resources, announcedMay19,2016, amount and security terms undisclosed. AndersenAdvisoryGroup and founder co-ownership are separately documented historical ownership, without inferring a new2016 personal check. The Danish Polaris manager is distinct from USPolarisPartners. Missing buyer profiles remain explicit dependencies, rather than bare placeholder investors. The company acquired100% of3Dfacto shares from private shareholders inJuly2014, with price undisclosed. That outgoing acquisition is separate from Configit financing. Current revenue, ARR, EBITDA, gross profit, Polaris assets under management and customer/partner relationships are not investment-round totals. No IPO, funding stage or amount is invented.

Leo James is a TRIMTECH academic co-founder, chief scientific adviser and scientific advisory board member. He leads research at the MRC Laboratory of Molecular Biology and is a Fellow of the Royal Society. His work established key mechanisms of TRIM21 and contributed to Trim-Away protein-degradation technology.

Alison Lawton independently chairs TRIMTECH’s board. Her biopharmaceutical leadership experience includes Kaleido Biosciences, Aura Biosciences, Genzyme and Sanofi. She has served on several public and private biotechnology boards and has extensive regulatory and market-access experience.

Albert Hwang serves as the Co-Head of Private Investments. Prior to Cercano, Albert was a senior investment professional at Vulcan Capital where he led private investments. He previously served in governance roles as director, observer, or advisor at several portfolio companies. Prior to Vulcan, Albert began his career at Jefferies & Company in the leveraged finance department. Albert holds a BS in economics from The Wharton School at the University of Pennsylvania.

Chris Orndorff is the Chief Executive Officer and Co-Chief Investment Officer of Cercano Management. Prior to founding Cercano in 2021, Chris was the Chief Investment Officer at Vulcan Capital, a private company started by Microsoft co-founder Paul G. Allen. Before Vulcan, Chris was a Senior Portfolio Manager at Western Asset, a Managing Principal at Payden & Rygel, and Second Vice President at Northern Trust. Chris currently serves on the board of directors for Bank OZK, one of the largest commercial real estate lenders. Chris holds an MBA from the University of Chicago, and a BS from Miami University. He is a CFA charterholder, and has published several monographs, including a book published by McGraw-Hill.

Joel Shoop serves as Chief Operating Officer. He is responsible for all financial and operational aspects of Cercano’s investment structuring, execution, valuation, reporting, treasury, and tax functions, paired with oversight of the firm’s information and technology strategy. Prior to joining Cercano, he served as the Head of Direct Structured Credit Finance for Castlelake, L.P. and held various oversight roles. Prior to Castlelake, Joel served in various leadership and managerial positions within finance and operations at MUFG Investor Services focused on fund administration and at Deloitte within the audit practice. He received his Master of Accountancy and BS from the University of Wisconsin-Madison and is a CPA.

Kim Holte serves as Chief Financial Officer of Cercano Management. She leads Cercano’s global finance function, including accounting, financial reporting, budgeting and forecasting, and financial controls. She also oversees all internal accounting financial operations. Prior to joining Cercano in 2021, Kim served as a senior manager at Baker Tilly, a nationwide public accounting firm. Kim is a licensed CPA and holds a BS in both Accounting and Finance from the University of Wisconsin La Crosse.

Malinda Khauv serves as Cercano’s Chief Compliance Officer. In this role, Malinda is responsible for implementing and overseeing Cercano’s core compliance program functions. Prior to joining Cercano, Malinda served as Chief Compliance Officer at Freestone Capital Management, helping define and manage the firm’s compliance program. Malinda also held a senior compliance position at IQ-EQ. Malinda earned a BA from the University of St. Thomas and an MBA from the University of Washington. She also holds the Investment Adviser Certified Compliance Professional (IACCP®) designation.

Michelle Brant is the Head of Human Resources, leading the company’s recruitment, development, total rewards, engagement, and retention strategies. Prior to Cercano Michelle served as the Director of HR at Vulcan Capital. Before Vulcan, she worked at Alaska Air Group, with both Alaska Airlines and Horizon Air. Michelle earned a BBA degree from the Foster School of Business at the University of Washington.

Minjie (MJ) Yu is published as MJ Yu in Cercano’s current venture-capital roster. His self-named public profile identifies Cercano Management in Singapore. The specific current global platform office is not published in the retrieved roster.

Rick Roberts is on the investment team with a focus on fintech, venture capital, and private equity. Before Cercano, Rick initiated research coverage on public and private companies globally at Vulcan Capital. Prior to Vulcan, Rick was a consultant to asset management firms and a senior partner at First Quadrant. He has been directly involved in the investment industry for over 30 years and spent his formative years at Bankers Trust and regional banks. Rick received his MBA from the University of Notre Dame and earned a BS in agriculture from the University of Arizona.

Stuart Nagae is the Co-Head of Venture Capital at Cercano. Prior to Cercano, Stuart was an investor at Vulcan Capital from 2002-2021. At Vulcan, Stuart invested across a range of asset classes including private equity, growth equity, wireless spectrum and venture capital. Before Vulcan, Stuart worked as an investment banker at Hambrecht & Quist and JPMorgan Chase & Co. Stuart received a BA in international relations from Stanford University.

Published as Tommy Teo in Cercano’s current venture-capital roster. Singapore’s regulator identifies Tommy Teo Zhi Zhuang as CEO and Executive Director of Cercano Management Asia Pte. Ltd.; this subsidiary office is distinct from his qualified global platform affiliation. Nera Telecommunications’ own 2023 annual report identifies the full name and describes his role leading Cercano’s Singapore investment team.

Trish Halper is currently the Co-Chief Investment Officer at Cercano. Prior to Cercano she was the Chief Investment Officer for the Global Family and Private Investment Offices at Northern Trust, responsible for over $50 billion in advisory assets. She also served as Deputy Chief Investment Officer at Wespath Benefits, overseeing a $30 billion multi asset class investment portfolio. Previously, she spent over twenty years at Chicago Equity Partners, a boutique quantitative asset management firm, as a quant researcher, portfolio manager, and Chief Investment Officer. Trish is a CFA charterholder and holds a MS in financial mathematics from the University of Chicago and a BS in mathematics from Loyola University Chicago.

YB Choi is Co-Head of Venture Capital at Cercano Management. Prior to joining Cercano, he served as a Director of Venture Capital at Vulcan Capital, leading investments and portfolio oversight for more than 50 companies across a broad range of industry sectors. Before Vulcan, he began his career as an analyst at Cowen & Co. before moving to Oppenheimer & Co. Inc., then later served as Manager in IP Acquisitions and Investments at Microsoft. YB received a BS in engineering and management systems from Columbia University.

Dean Clift leads biology at TRIMTECH. Following his Edinburgh doctorate, he worked at Cambridge’s MRC Laboratory of Molecular Biology with Melina Schuh and Leo James. His research helped establish Trim-Away technology and investigate activation of the TRIM21 ubiquitin ligase.

Andrea Testa is TRIMTECH vice president of chemistry and a scientific co-founder of Amphista Therapeutics. His targeted-protein-degradation experience includes work in Alessio Ciulli’s Dundee laboratory and developing oral, brain-penetrant degraders at Amphista. He holds an Aberdeen doctorate and a Milan chemistry master’s.

Alex Alanine heads chemistry at TRIMTECH. His background includes more than two decades at Roche, neuroscience medicinal chemistry leadership, and the COO role at Nanna Therapeutics before its acquisition by Astellas. He earned his doctorate at Leeds and has advised biotechnology discovery programmes.

Nicola (Nicki) Thompson is CEO of TRIMTECH Therapeutics. She previously founded and led Amphista Therapeutics and held drug-discovery and business-development leadership roles at Roche and GSK. Her experience includes Nanna Therapeutics, Camena Bioscience and Syntaxin; the current company biography also identifies her as Nascent Therapeutics board chair.

Alexander James Stevens is the current registered statutory director of NielsenVenturesUKLimited, company13302973, appointedJune10,2026 according toCompaniesHouse. The UK company is associated with2xN’s earlier published founding/operating people; this legal affiliation does not assert a2xN investment-management title or identify him with the separate PlanetAVentures professional namedAlexanderStevens. A genuine matching public portrait and further professional biography were not verified.

Kris Kaczmarek joined2xN as QuantumInvestmentAssociate inMarch2023. He previously headed product at ORCAComputing, developing its quantum-memory technology through Oxford doctoral research. His employer-published biography describes photonics research at Geneva,Oxford,Warsaw andICFO. QDNLParticipations announced his move asInvestmentDirector onOctober29,2024, corroborated by his own departure post, so his2xN role is historical.

Evgenia Sopochkina was published as2xN Principal after joining inApril2021. Her primary biography describes RoundHillVentures experience, founding an AI talent-management startup, and finance work at Barclays, BNPParibas andCreditAgricole. She holds HECParis management and LondonBusinessSchool MBA qualifications. Later primary professional announcements publish EvgeniaMacpherson with the same2xN/AI-startup/education background. Her2xN affiliation is dated because the old directory is hidden and later employer roles exist; an unverified current title is not asserted.

Johan Maunsbach was published as2xN Partner and COO in its earlier directory and2023 European Quantum Technology Conference. Qualified as a lawyer in Sweden and England and Wales, he spent a decade at PartnersGroup and previously served as GPBullhound Partner/COO. His original biography describes private-market transaction management and an Uppsala LL.M. His current DMXPartners biography identifies the2xN role as prior; CompaniesHouse confirms his associated UK statutory directorship endedJune19,2026, so the operating affiliation is qualified as historical.

Niels Nielsen co-founded2xN and leads its quantum-technology investment focus. He was an early Cambridge Quantum investor and chairman before its merger with Honeywell Quantum Solutions into Quantinuum, where he became a board member. His primary biography describes experience building financial-services businesses including Zedra, Vistra and LGTVestra and ownership in AzureHotels. He holds a Brown business/economics degree and a Yale MBA. Institutional2xN investments are distinguished from his personal investments and other family-office businesses.

2xN is a London-based quantum-inspired early-stage investment platform co-founded in2021 by technology operator LarsFjeldsoe-Nielsen and entrepreneur/quantum investor NielsNielsen. Its mandate combines quantum hardware/software and other technology businesses with founder networks and operating support. It is distinct from the2degrees private office atweare2degrees.com and from unrelated2XNLimited11123056. Primary portfolio-issuer and institutional-LP sources identify its subscribing Luxembourg vehicle as2xN VentureFundI,S.C.Sp., registeredB265180 and active LEI894500YKEVILABDAQ260, with separate GP2xNFundIGPS.àr.l.,B265060/LEI894500YK9BYTNC1F2I35. The legal fund and GP are not treated as duplicate checks or fundraises. NielsenVenturesUKLimited13302973 is an associated UK services/advisory company with the same earlier operating/founding people; its original2025 accounts report intercompany service recharges, not portfolio cash or a fund close. Current regulatory permissions or an exact exclusive platform-to-UK-operator legal identity are not inferred without the unavailable original regulatory disclosure. The live website currently hides its earlier full team directory in HTML comments; those genuine biographies and portraits are retained as dated source material. JohanMaunsbach, EvgeniaSopochkina and KrisKaczmarek have later professional affiliations, and associated statutory officer resignations are separately qualified. Genuine roster entries are distinguished from unnamed asset-library photos. Primary financing sources verify institutional2xN backing of Kvantify, SparrowQuantum and QSimulate; the founders’ personal track records and co-investor logos are not automatically assigned to the fund. Kvantify’s2024 seed and2025 first-close participation are company-owned finance callbacks on existing records. The media-reported2021 USD50M and2022 USD120M funds are not assigned to separate closed legal funds without primary close/vehicle proof. EIFO’s reported fund equity/results/ownership are balances and LP holdings, not original committed or closed corpus.

Co-head of BNP Paribas Asset Management Alts’ Agility Co-Invest strategy. The June 29, 2026 final-close announcement identifies his leadership of the European mid-cap private equity co-investment programme alongside Lionel Gomez.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Investor, Entrepreneur, Operator and Board Member. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Cardiology specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Head of Real Assets for BNP Paribas Asset Management Alts, published in the September 7, 2026 European Junior Infrastructure Debt Fund II final-close announcement. The platform’s infrastructure debt strategy finances energy transition, clean mobility, digital infrastructure and utilities.

Co-head of BNP Paribas Asset Management Alts’ Agility Co-Invest strategy. The June 29, 2026 final-close announcement identifies his leadership of the European mid-cap private equity co-investment programme alongside Damien Fournier.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Diabetes, business development/commercial specialist and investor. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Oncology specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Global health specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Global health specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

Published as a key adviser to the Alts global healthcare strategy, with the specialty: Clinical Ophthalmology specialist. This is a scoped advisory affiliation, rather than employment or statutory board membership.

BNP Paribas Asset Management Alts, formerly AXA IM Alts, is the alternative investments platform of BNP Paribas Asset Management. It invests across private equity, infrastructure, real estate and alternative credit, using equity and debt to finance companies, buildings and essential infrastructure. Its impact investing programmes focus on affordable healthcare, financial inclusion, climate innovation, biodiversity and natural capital, alongside commercial investment returns. The global healthcare private equity strategy backs late-stage clinical development and early commercialization of medical devices, diagnostics, drugs and vaccines designed to be effective, durable and affordable in both high-income and lower-resource markets. It typically leads or co-leads investments and supports clinical development, regulatory pathways, manufacturing and international market access. Its therapeutic interests include maternal and child health, vision, infectious diseases, diabetes, respiratory disease, cardiovascular care and oncology. The current platform combines AXA IM Alts, BNP Paribas Private Markets and BNP Paribas Real Estate Investment Management activities following BNP Paribas’s acquisition of AXA Investment Managers in July 2025. Its investment teams and governance represent an operating platform spanning legal entities, rather than the parent bank or AXA Venture Partners.

Global Head of Private Equity for BNP Paribas Asset Management Alts. The same current management card also names him CEO of the separate BNPP AM Prime platform; the Prime office is kept as context rather than an Alts legal-entity employment claim.

Wende Hutton is a healthcare venture investor named to Mission Bay Capital’s outside investment advisory committee. Canaan’s own biography identifies her general-partner investing in therapeutics and medical devices, following earlier Mayfield investing and operating roles at GenPharm and Nellcor. She studied human biology at Stanford and earned an MBA at Harvard. Mission Bay’s published committee role is outside advice, not presumed fund employment or a personally funded company check.

John Wadsworth Jr is named in Mission Bay Capital’s public investment advisory committee, whose undated directory describes his outside Manitou Ventures managing-director affiliation. UCSF’s October2009 fund launch names John Wadsworth and Brook Byers as leaders of its pro bono advisory committee. This record concerns the investment adviser in that exact institutional context, not unrelated Wadsworth names. The affiliation is advisory and does not establish employment, a fund commitment or a personal company investment.

Lennart Mucke serves on Dolby Family Ventures’ scientific advisory board. His research examines mechanisms of memory loss and neurological dysfunction in Alzheimer’s disease and related disorders. His published biography describes leadership at Gladstone’s neurological-disease institute and UCSF neuroscience and neurology appointments, with earlier clinical and neurobiology training in Germany and the United States. The advisory role is distinct from executive management of the investment firm.

Michál de Beer joined Dolby Family Ventures in2026 as an analyst supporting its frontier-technology fund. He earned an economics bachelor’s degree at the University of California, Berkeley and interned at Bank of America Merrill Lynch and Rand Merchant Bank. The firm’s biography describes his student-athlete rugby achievements and Johannesburg background. An exact appointment day is not disclosed.

Alona Cochran is office manager and executive assistant at Dolby Family Ventures. The firm dates her work with it to2014 while employed by Levensohn Venture Partners, which she joined in2006. Her earlier experience includes executive assistance in J.P. Morgan’s technology, media and telecom investment-banking group and other financial-services firms. She earned a business-administration bachelor’s degree at the University of San Francisco.

Carsten Gjørtler Salling, professionally also Carsten Salling, is named as general partner in Dreamcraft’s legacy own media kit and in executive-board/board capacities in its primary signed2022 manager accounts. The exact full name is present in the digital-signature execution section. His absence from the current Dreamcraft four-partner roster is explicitly qualified; no current2026 employment or exact ending day is inferred.

Mei Liang is vice president of finance at Dolby Family Ventures, which dates her arrival to2024. She previously worked as financial controller and senior vice president at Riverwood Capital and held corporate-finance roles covering reporting and internal controls. Earlier she worked in Arthur Andersen’s assurance and business-advisory practice. She earned an accounting bachelor’s degree from Santa Clara University.

Usua Amanam is a senior associate at Dolby Family Ventures supporting technology and climate investments. He joined in2023 as an associate, after energy-transition investment work at NGP Energy Capital Management and consulting at PowerAdvocate. He holds Stanford bachelor’s, master’s and doctoral degrees in energy resources engineering. His doctoral research addressed chemical kinetics, nanocatalysts and nanoparticle transport.

Pascal Levensohn is executive chairman of Dolby Family Ventures. He joined in2014 after advising the family’s direct technology portfolio since2012. He founded Levensohn Venture Partners and has experience in investment management and venture-company governance. His current own biography dates his appointment as chair of Cambridge University Innovation Hub’s Global Advisory Board to April2026; his National Venture Capital Association directorship was2007–2011.

Christian Kirk Rasmussen is a founding partner in Dreamcraft’s own legacy media kit and a named director in its signed2022 manager annual report. Better Collective’s current own press kit identifies him as co-founder/co-CEO and publishes the original portrait retained here. His absence from Dreamcraft’s current four-partner site means continued current partnership status is not inferred; no exact ending date is published in reviewed primary sources.

René Rechtman is a current Dreamcraft partner, joining its published partnership with Nikolaj Nyholm. He is founder and CEO of Moonbug Entertainment according to its own2024 issuer announcement. Better Collective’s primary2023 annual report provides his authentic original caption-bound portrait and identifies an MSc in Politics and International Relations from Copenhagen University, prior Walt Disney/Maker Studios leadership and earlier AOL, Goviral and TradeDoubler roles. Historical board roles remain dated; no personal check is inferred.

Nikolaj Nyholm is a current partner in Dreamcraft’s own four-person partnership. His own announcement describes joining with René Rechtman to support founders with direct audience/community relationships across gaming, media, sports, music and infrastructure. The primary Astralis2021 annual report provides his caption-bound original portrait and dated chairman biography; historical Astralis roles are not presented as current2026 employment.

Dreamcraft is a Copenhagen/London venture investment partnership. Its own legal notice identifies Dreamcraft Ventures Management ApS, Danish CVR40209808, as the regulated-manager/site legal entity; primary2022 audited manager accounts establish the same exact registration and Daniel Nyvang-Székely Mariussen’s shortened professional name Daniel Mariussen. The current partnership lists Daniel Mariussen, Jesper Søgaard, Nikolaj Nyholm and René Rechtman. Its current post-AI thesis focuses on scarce human attention, proprietary audiences and communities across gaming, media, betting, sports and the enabling data/infrastructure. Earlier published strategy targeted European/Nordic pre-seed through SeriesA in B2B SaaS, digital entertainment and fintech, with operational venture-engineering support. Historical quantum-computing investment in Kvantify and AI portfolio publications remain distinct from the current specialization. Own fund disclosures identify master Dreamcraft Ventures Fund II K/S CVR42626716 and feeder42879150; the feeder invests exclusively in the master and does not provide a second EUR66M raise. The manager announced FundII final close at EUR66M inJune2024 after an earlier EUR40M first close; these are one fund’s cumulative snapshots. The separate FundI vehicle CVR40498230 is verified by its signed2025 annual report, previously Heritage-named in registry-derived listings; its DKK200M committed capital/uncalled snapshot is qualified separately from AUM, NAV or a final closing date. The gaming software Company Dreamcraft at dreamcraft.com is a distinct homonym. Corporate shareholder/GP/management co-invest entities and staff directorships do not prove personal cash investments.

Daniel Mariussen is a current partner at Dreamcraft in Copenhagen/London and was a general partner in its earlier own media kit. The manager’s signed2022 annual report uses Daniel Nyvang Mariussen on its governance pages and Daniel Nyvang-Székely Mariussen in the execution signatures, providing the full/short-name bridge. He serves in the manager’s executive board and board in that dated document. His quoted operational venture-engineering approach and historical Kvantify board capacity are distinct from individual cash participation.

Jesper Søgaard is a current Dreamcraft partner and founding partner in its own legacy media kit. He is also co-founder and co-CEO of Better Collective, whose own press kit supplies his genuine original portrait. Better Collective’s primary annual reports identify his Copenhagen University MSc in Political Science and founding-member role at Dreamcraft Ventures Management ApS. He is a named manager director in signed2022 accounts; these institutional roles do not establish a personal investment ticket.

Vivian Dang is an accounting and financial-operations professional published as controller at Mission Bay Capital, where its biography says she joined in2010 and provides part-time CFO services. She previously served as controller at Mohr Davidow Ventures and worked in tax and audit at Andersen and Deloitte. She earned an accounting degree at the University of California Riverside. Her financial-operations practice and part-time support role are distinguished from full-time investment-partner employment.

Mission Bay Capital is a San Francisco early-stage life-science venture investment platform founded in August2009 to support bioscience entrepreneurs emerging from the University of California and other research institutions. It operates alongside MBC BioLabs shared laboratory infrastructure and funds biotechnology, medical diagnostics, therapeutic discovery and other research-derived technologies. The original brand is related to Mission BioCapital but remains a distinct historical fund platform: its own landing page separately links Mission Bay Capital and Mission BioCapital, while the March9,2023 QurAlis issuer explicitly names both investors. The relationship does not establish that they made the same check. Current2026 SEC filings distinguish FundI adviser Mission Bay Capital Management Inc (CRD288916), FundII adviser MBC FII Management LLC (CRD289161) with Mission Bay Capital Management LLC as fundmanager, and FundIII adviser Awesome Enablers LLC (CRD298755) with GP MBC Management III LLC. Those filings separately list Mission BioCapital Management Company LLC as a related adviser; shared team/ownership is not a legal merger. The brand profile groups its own historic Mission Bay vehicles with explicit per-fund adviser identities, and does not represent the separate Mission BioCapital FundI/V/VI as Mission Bay capital. CurrentMarch2026 filings confirm Douglas Kingsley Crawford and Robert Glenn Blazej in the relevant management rosters. The undated public website publishes five management/operations people and six outside investment advisory committee members; those advisory affiliations and historical outside titles are not presumed current fund employment. SEC adds Regis Kelly as FundI manager President. Relevant primary institutional financing includes QurAlis ALS/FTD precision-therapy research. FundI launched with USD7.5M disclosedOctober26,2009, an initial launch amount rather than a final later total; FundII USD25M is retrospectively confirmed by the2019 own release with finalclose day unpublished; FundIII actually closedUSD60M announcedSeptember16,2019. Its master and Cayman feeder are recorded separately but capital is counted once at the master; grossassets/portfolio financing/LP commitments are not new fund cash. Exact QurAlis2023 fund allocation and institutional ticket remain undisclosed. Mission Bay Capital Partners real-estate syndication is unrelated.

Onn C. Lee leads shared corporate accounting that includes Alexandria’s venture portfolio. She joined Alexandria in 2009 and became EVP in March 2022, with exact days unverified. Her earlier work was in Deloitte assurance. She is a CPA and studied economics and accounting at UCLA. This support remit does not establish investment-partner authority.

Blake L. Stevens oversees Alexandria’s Research Triangle venture portfolio and national agtech investment strategy, alongside regional real-estate leadership. His EVP promotion was in January 2026. Earlier positions include LaunchLabs management, investing at Harris & Harris, and technical work at HZO. He holds materials-science degrees from Cornell and Northwestern.

Hallie E. Kuhn co-leads Alexandria’s life-science activities and oversees venture investments alongside capital-markets duties. Her current EVP appointment dates to January 2026, with the precise day unverified. She previously worked at LS Polaris and ClearView. Her education includes a Harvard systems-biology doctorate and Harvey Mudd bachelor’s degree.

Jenna Foger manages Alexandria’s venture portfolio and Strategic Capital Platform as a life-science co-lead. She became EVP in January 2026 after earlier leadership roles beginning in 2014. Her background includes Windham venture investing, consulting and Rockefeller neurobiology research; she studied biotechnology at Columbia and neuroscience/psychology at Penn.

Quaternity ApS is a privately held Danish corporate holding company, CVR41493607, associated with biotechnology and precision medicine through disclosed backing of gMendel. Its own2025 annual financial statements, approved and signed June25,2026, identify registered office Hørsholm, Denmark and director Christos Kyriakidis, the same executive publicly known as gMendel co-founder/CEO Chris Kyriakidis. The signed statements describe its primary activities as a holding company and related business; this is not evidence of an independent external-LP venture manager. gMendel’s2022 signed annual report identifies Quaternity as joint-tax-group administration company; its2022,2023 and2025 issuer reviews separately name Quaternity among private funding supporters. Those corporate support disclosures are distinguished from personal founder checks, exact individual allocation, ownership percentage or an inferred financing instrument. The company-controlled public LinkedIn page describes biotechnology research and names Chris Kyriakidis as its sole publicly visible professional affiliation. Its generic2–10employee range is not a verified staff roster: the actual2025 statements report zero average employees. The published director is included as governance, not an invented paid employee. No genuine company brandmark, additional verified public management names, external-LP funds, fund closing amounts or unrelated portfolio investments were established. The LinkedIn child-image cover and annual-report accountant Beierholm logo are excluded from the company image. Share capital, group receivables, accounting assets and intercompany tax balances are not fund closings or priced funding tickets.

A & B (HK) Company Limited is a privately controlled Hong Kong healthcare and life-science investment company. Acticor’s regulator-approved2021 registration document identifies A&B Venture as a family-office investment vehicle led by Huaizheng Peng. The2019 SEC joint filing confirms that HongKong A&B is wholly owned by A&B BrotherLimited, a distinct BritishVirginIslands company wholly owned by LamKong. It is associated with ChinaMedicalSystem through shared ultimate leadership/control, but it is not CMSMedicalVentureInvestment(HK) or a wholly owned CMSoperating subsidiary. Separate legal buyers retain separate investments; Lam’s control of companies is not evidence of his direct personal check. OfficialGLEIF record549300DB8X2RW1QBWG65 supplies exact legal name, HongKong registry64274051 and UnitA,11/F,ChungPontCommercialBuilding,300HennessyRoad,WanChai address. Entity status is reportedACTIVE, while the LEI registration isLAPSED and last updatedAugust2024; this is not fresh confirmation of every current corporate role. The2019 SEC ScheduleA names LamKong as director and HuaizhengPeng as chief executive, independently consistent with Acticor’s2021 description. Those two published subsidiary leadership affiliations are recorded historically; current CMSparent roles on their full existing biographies remain separate. Their authentic CMS-published individual portraits are reused unchanged. No independently authenticated A&B logo, dedicated website or complete current subsidiary staff directory was located, and no CMSlogo is substituted merely because executives are shared. A&B invested corporate working capital in international product-focused life-science companies. In2019 it paid approximatelyGBP4M for Midatech shares and warrants, separately from CMSHK’s approximatelyGBP4M subscription; licensing royalties, unexercisedwarrants and indirectparentownership are not extra cash. Actual Acticor2018SeriesB participation is confirmed by issuer and statutory document, with subscribing individual ticket unpublished. Its agreement was signedJuly31,2018 alongside separateCMSlicensing/equity agreements; that signing date is not invented as exact publicannouncement or completedcashclosing. The available profile discloses no pooledexternalLPfund closings. Historical financial holdings are not assertions of current portfolio status, successful clinical trials or approved stroke therapy; Acticor entered judicialliquidation inJanuary2025.

iFutura ApS is a Danish private holding and technology/business-development consulting company, CVR32469736. Its signed2024 annual report, approvedMay20,2025, identifies the exact legal entity, registered office atSkovbrynet26,2800KongensLyngby and executive-board director Zoran Velkoski. It is represented as a corporate holding investor rather than an external-LP venture fund manager. The original filing is a management-approved, accountant-compiled annual report expressly not audited. The company’s own public LinkedIn profile describes a technology portfolio including gMendel ApS, OneUp Engineering A/S, Embedded Nu and Analogue Alchemy. This provides verified AI/genomics and deep-technology relevance: gMendel develops AI-based genetic diagnostics, OneUp’s published scope includes hardware/FPGA/software/embedded/cloud engineering, and Embedded Nu focuses on embedded systems and IoT. These own published portfolio relationships do not establish individual financing tickets, full ownership or source-verified legal identities of every named operating business. The profile’s branding refers to engineering and lists1999 as a founding year; secondary registry reproductions instead identify the Danish ApS in2009. A precise legal incorporation date or continuity bridge to a1999 predecessor was not verified in the primary annual report, so the structured founding year remains unknown. The annual-report registered office and the LinkedIn Copenhagen location are distinguished. gMendel’s own ecosystem page explicitly identifies iFutura and Quaternity as private angel investors. Its2022 year-in-review names actual private backing, its2023 report names follow-on private support, and the2025 review publishedJanuary16,2026 says limited funding was secured from iFutura and Quaternity while the full planned financing round did not close. These are distinct source-qualified private funding disclosures; individual amounts, financing instruments and precise payment days are unpublished. They are not converted into an assumed full seed round, presumed completion of all intended fundraising or a personal Zoran investment. Zoran Velkoski is the only publicly named company professional in the own profile and original financial report. His existing gMendel CTO/cofounder identity, authentic portrait and professional biography are preserved, and the holding-company director role is added separately. Neither gMendel’s team nor operating-company employees are represented as the holding company’s own staff. The official-profile logo is genuine original company media. The linked website ifutura.eu was not publicly accessible during the audit; its URL is source-reported rather than evidence of a currently functioning public website. No primary source establishes an outside LP fund, fundraising close or fixed venture programme. The annual report’s DKK125000 share capital, balance-sheet securities, equity and receivables are corporate accounting items rather than new company financing rounds or investment-fund closes. A reported portfolio name alone is not a new cash transaction; precise additional company profiles and financial links require independent full-source verification.

Wingbits co-founder with a software engineering background. Its founder biography labels him CTO/CEO of operating company Airbits, while structured company data labels him CEO.

Jeff Wilson is published by Wingbits as Head of Product and Commercial Services, with expertise in ADS-B, aircraft surveillance and commercial aviation data services.

Ray Buckton is credited as Marketing in Wingbits’ published author biography, covering its network and community developments. Current employment status is unverified.

Wingbits co-founder. Its visible founder biography labels him CEO; structured company data labels him CCO. The current title conflict is unresolved.

Silvano Garnerone publicly announced joining Wingbits as Head of Data Science. The appointment is directly published by him; current membership and exact start date are unverified.

Yanal Hammouda leads market expansion according to Wingbits’ published biography, working on international growth, market entry and localization.

Wingbits develops a flight-tracking and aviation intelligence platform backed by community-operated ADS-B receivers. Its decentralized physical infrastructure network rewards contributors with WINGS tokens for supplying aircraft telemetry, and signs data at the receiver to support data integrity. The company sells live and historical flight data through APIs and dashboards to aviation businesses and researchers, with tools for aircraft tracking, airspace analysis, GPS interference mapping and TCAS event replay. Wingbits AI connects aviation data to AI assistants and agents, while Wingö is a public-beta conversational assistant on its live map that answers aircraft and location queries in plain language. Wingbits is the operating brand of Sweden’s Airbits AB; the separately incorporated Hexagon Foundation Ltd handles token issuance.

Doorstep.ai, branded Doorstep and operated by Doing Doorstep Better Inc., builds indoor and outdoor delivery tracking software for logistics and e-commerce platforms. Its SDK integrates into an existing driver app and combines smartphone sensor signals to automatically identify parking, building entrances, floors and the final drop-off, including environments where ordinary GPS is unreliable. Operations and customer-support teams use its dashboard and delivery-event data to investigate disputed deliveries, identify delays, improve arrival-time estimates and provide precise driver wayfinding. Its predictive delivery-intelligence platform is designed to reduce failed deliveries and refund fraud without requiring additional building hardware. Antler described its earlier product as AI-powered visual guidance; the current product explanation emphasizes sensor-fusion algorithms and delivery intelligence. The company is based in New York.

QMill is a Finnish quantum-algorithm and software company founded in2024 and based in Espoo. It develops software for quantum-powered information security and hybrid quantum-classical optimization in telecommunications, transport, energy, finance and defense. Its Quantum Advantage Services platform provides researcher and developer tools, including an AI-powered circuit-compression service that reduces gate counts and circuit depth while preserving a circuit’s function, with hosted and private deployment plus API and SDK access. The company is developing quantum key-establishment and verifiable-computation methods, has demonstrated mobile-network encryption with Telia, and is working with ESL Shipping on assigning cargo across vessel fleets. Its broader quantum-advantage performance estimates are based on mathematical analysis and simulations; they are research results rather than a claim that universal industrial quantum advantage has already been demonstrated.

Clayton Leite is published by QMill as Quantum AI Engineer. Researches AI-driven quantum-circuit design and optimization. Own technical blog establishes affiliation, and co-founder repost quotes the original company post publishing QuantumAIEngineer title.

David Karpuk is published by QMill as Principal Quantum Algorithm Engineer. Develops the mathematics behind practical quantum algorithms for noisy intermediate-scale hardware; previous academic and data-science experience.

Debojyoti Mahapatra is published by QMill as Team member (role not published). Own companySeptember2026posts explicitly identify his participation in the QMill booth and quote him about the event. Exact job title is not published in these sources.

Elias Vakkuri is published by QMill as Software Engineer. Software, cloud, digital strategy and AI/ML experience; MSc in industrial engineering and management from Tampere University.

Ernesto Campos is published by QMill as Quantum Algorithms Engineer. Quantum-computing PhD researching variational algorithms, tensor networks and quantum-classical machine learning; prior teaching and research at ÉTS Montreal and Monterrey Institute of Technology.

Hannu Kauppinen is published by QMill as Chief Executive Officer and Co-Founder. Former Nokia Technologies CTO and Head of Nokia Research Center; co-founder of location-technology company Quuppa.

Janne Heikkinen is published by QMill as Chief Product Officer. Own June2026company hackathon report identifies ChiefProductOfficer; participants and winning students are external, not employees.

Jouni Peltonen is published by QMill as Team member (role not published). Own companySeptember2026posts explicitly call him a colleague and quote his job at QMill alongside a University of Jyväskylä PhD. Exact job title is unpublished in the reviewed company sources.

Juha Koponen is published by QMill as Senior Quantum Product Manager. Own individual profile reposts QMill appointment announcement; own companySeptember2026post also identifies him as a colleague demonstrating QMill technology. Distinct from other JuhaKoponen professionals, none native matched.

Mikko Möttönen is published by QMill as Chief Scientist and Co-Founder. Professor of Quantum Technology at Aalto University and co-founder of quantum-computer hardware company IQM; active quantum research and technology commercialization.

Pekka Lundmark is published by QMill as Board Member. Former President and CEO of Nokia with earlier executive experience in communications, energy and industry. Own QMill March2026newsroom and current company posts corroborate continuing board affiliation.

Peter Sarlin is a co-founder of SiloAI and professor of practice at Aalto University, as identified in QMill’s March7,2025issuer announcement of his personal angel investment. This is a personal check, not a SiloAI, AMD or other manager investment.

Sami Oksanen is published by QMill as Head of Sales. Sales and business-development experience in ICT and energy industries; own company blog says he joined in April2025. Current own2026company posts retain Head of Sales.

Tommi Tenkanen is published by QMill as Head of Business Development and Strategy. Current own companySeptember2026conference announcement publishes exact title; theoretical-physics and strategy background is corroborated by the event organizer.

Toni Annala is published by QMill as Chief Algorithm Engineer and Co-Founder. Mathematician with published appointments at the Institute for Advanced Study, Princeton, University of Chicago and University of Toronto, and recipient of the2023CMSBlairSpearmanPrize.

Ville Kotovirta is published by QMill as Chief Technology Officer and Co-Founder. Previously led the quantum algorithms and software team at VTT Technical Research Centre of Finland.

Takahiro Mukohira, commonly published as Tak Mukohira, is cofounder and CEO of TNAX Biopharma, which he has led since its March 2018 founding. TNAX’s own biography confirms his former President role at MP Healthcare Venture Management, the Boston corporate venture arm of Mitsubishi Tanabe Pharma. He previously led business development at Life Science Institute in the Mitsubishi Chemical group and has more than 35 years of pharmaceutical and healthcare experience spanning business development, corporate strategy and international business. He earned an SM in Management of Technology from MIT Sloan and a BS in Pharmaceutical Sciences from Kyoto University. His MPH presidency is historical; its exact tenure dates are not established from these primary biographies.

Tetsuro Iwata, also published as Tetsu Iwata, was Senior Manager at MP Healthcare Venture Management from July 2009 to August 2015 according to his own professional chronology. The primary RESI 2014 conference biography independently names his MPH role and July 2009 start and describes prior pharmaceutical business-development, licensing, sales, marketing and project-management responsibilities, including cardiovascular, stroke, renal and respiratory areas. He studied pharmaceutical sciences at Meiji Pharmaceutical University. Later roles at Mitsubishi Tanabe Pharma and its US holding company are distinct from his historical MPH investment role. No current MPH title or personal investment is inferred, and month-only dates remain without invented days.

Naoya Sato formerly served as Director of MP Healthcare Venture Management from March 2015 to March 2019 according to his own public professional chronology. Kauffman Fellows’ primary Laura Tadvalkar biography independently identifies him as her MPH Director mentor. His earlier pharmaceutical research and management work included Mitsubishi Tanabe Pharma and Tanabe Research Laboratories USA, with autoimmune, psychiatric and neurological research using human induced pluripotent stem cells. His public profile subsequently identifies business-development work at Mitsubishi Tanabe Pharma, academic research-administration work at Chiba University from April 2023 to February 2026, and Chief Operating Officer of TOKIWA-Bio from March 2026. This is a historical MPH role, not an assertion of current employment; month-only dates remain unconverted to invented days.

Shota Ozawa was a Director at MP Healthcare Venture Management from June 2023 to June 2026 according to his own public professional profile. LiberoThera’s August 1, 2024 primary financing announcement independently names him as MPH Director when he joined that company’s board. His profile places him in Tanabe Pharma’s Transformation Division from July 2026, following earlier research and business-development positions at Mitsubishi Tanabe Pharma. His education includes medicine at Kyoto University, biophysics and biochemistry at the University of Tokyo and an MBA at UMass Lowell. AMED’s current registered-VC list still names him as an MPH contact; this registration is qualified against the subsequent employment chronology, rather than presented as proof of a current Director appointment. Source employment dates are month-only.

MP Healthcare Venture Management, Inc. (MPH) is a corporate life-science venture investor established in August 2006, with its current parent-group directory locating it at 245 Main Street, second floor, Cambridge, Massachusetts. The Boston label and former Arch Street address in older announcements are historical. It backs seed and early-stage companies developing innovative therapeutics and platform technologies across North America, Europe and Japan, with particular interest in neurodegeneration, immunology, oncology and rare diseases. It is part of the Tanabe Pharma group, historically known as Mitsubishi Tanabe Pharma: the parent’s June 2023 disclosure specifically identified MPH as a wholly owned subsidiary of Mitsubishi Tanabe Pharma America, itself wholly owned by the Japanese parent. The pharmaceutical parent moved under Bain Capital-advised ownership on July 1, 2025 and changed its name to Tanabe Pharma Corporation on December 1, 2025. Current Tanabe primary materials continue to list MPH as its investment subsidiary. Older descriptions of joint Mitsubishi Chemical ownership must therefore be read in their historical context. MPH is a legally distinct venture subsidiary; the parent’s investments and commercial pharmaceutical collaborations are not automatically MPH checks. Primary QurAlis announcements name MPH in its 2018 seed financing, 2020 USD42 million Series A and 2023 USD88 million Series B, supporting its direct neuroscience relevance. Its other documented investment history includes RNA technologies, novel protein degradation and computational or biomarker approaches to drug discovery. This technology focus does not establish approvals or clinical efficacy of portfolio products. Published team records require careful date qualification: Jeffrey Moore had moved to Oxford Science Enterprises by September 2026, Shota Ozawa’s own chronology records the end of his MPH Directorship in June 2026, and Laura Tadvalkar, Naoya Sato, Tetsuro Iwata and Takahiro Mukohira have primary-supported historical roles. AMED’s registered-VC directory still names Moore and Ozawa as contacts; those contact records are not treated as evidence that their former operating titles remain current. The full current operating roster and Moore’s successor are not independently established. Parent capital allocations, investment reserves and government ecosystem-support eligibility are not external LP fund closes; no independent fund close is asserted.

Novocuff develops the Cervical Control System (CCS), an obstetric medical device designed to support and close the cervix, retain amniotic fluid after preterm prelabor rupture of membranes (PPROM), and maintain cervical length in pregnancies affected by cervical shortening. Its aim is to extend pregnancy and reduce prematurity; its safety and effectiveness remain under clinical evaluation. Following two first-in-human feasibility studies in Panama, the company opened the FDA IDE-authorized RETAIN pivotal study in 2025. This randomized, multicenter US trial compares CCS plus standard care with standard care alone for singleton pregnancies affected by PPROM, with planned enrollment of up to 272 participants. The device remains investigational and has no marketing-approval claim on the company’s current website. Founded by Amy Degenkolb and Donald Lee in 2021, Novocuff is a company-in-residence at Fogarty Innovation in Mountain View, California.

Amelia “Amy” Degenkolb is Novocuff’s co-founder and CEO. The current company roster publishes Amy Degenkolb; the issuer’s Series A announcement explicitly supplies the Amelia/Amy alias.

Curt LaBelle is published by Novocuff as Director (issuer July2024; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Donald Lee is published by Novocuff as Co-founder & COO. This role is listed on the company’s current own team page.

Jane Price is published by Novocuff as Clinical Research Manager. This role is listed on the company’s current own team page.

Kathryn Wine is published by Novocuff as VP of Clinical Affairs. This role is listed on the company’s current own team page.

Lilly deSouza Burr is published by Novocuff as Director (issuer July2024; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Lisa Tehrani is published by Novocuff as Director of Marketing (own legacy page; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Marissa VanDeVeer is published by Novocuff as Clinical Engineer. This role is listed on the company’s current own team page.

Rich Ferrick is published by Novocuff as Quality Assurance. This role is listed on the company’s current own team page.

Shacey Petrovic is published by Novocuff as Chair of the Board (issuer July2024; current status unverified). The source qualification in the role distinguishes this publication from verified current company membership.

Vaishali Suraj is published by Novocuff as Sr. Director of Clinical Affairs. This role is listed on the company’s current own team page.

Criticality is an early-stage venture investment brand backing founders working on technically difficult problems with urgent practical applications. It invests at seed and Series A in deep technology, foundational infrastructure and overlooked or underserved systems, with disclosed portfolio areas including AI for drug discovery and clinical trials, healthcare delivery, advanced housing construction and other physical-world technologies. Its current published portfolio includes OM Therapeutics, Karoo Health, Standard Electron, Orion Sleep, Cedar, Vital Care, Dream and The American Housing Corporation. The strategy combines long-term technical conviction with support for scaling companies and institutional partnerships. Criticality builds on Antler’s US platform and complements its pre-seed investing, while its launch announcement describes the fund as independently managed. Its first fund is anchored by the New Mexico State Investment Council, aligning commercial investment returns with regional development and broader economic resilience.

T. Denny Sanford was a businessman, life-sciences investor and philanthropist. EnBiotix’s original2021 financing announcement identifies Sanford Biosciences LLC as his life-sciences investment arm. His professional biography records University of Minnesota graduation1959, industrial distribution/manufacturing entrepreneurship, and the1986 purchase of a Sioux Falls bank followed by United National Corporation, First Premier Bank and Premier Bankcard. He supported biomedical research and education at multiple legally separate institutions. Sanford Burnham Prebys confirms he diedJuly18,2026. His private investor affiliation is historical; charitable donations and company checks are not conflated, and no current succession manager is inferred.

Sanford Biosciences LLC (SBL) is a private life-sciences investment organization explicitly identified in EnBiotix’s December29,2021 financing announcement as the life-sciences investment arm of T. Denny Sanford. Its verified financing activity includes QurAlis, a precision-medicine developer targeting ALS and genetically related frontotemporal degeneration. This makes it a relevant neuroscience and biotechnology investor, rather than an AI-software operating company or a public grant programme. QurAlis names Sanford Biosciences as an existing-investor participant in its USD42million Series A announced May13,2020 and USD88million Series B announced March9,2023. Those figures are total issuer rounds, not Sanford’s individual investment checks; allocations and fund-vehicle attribution are undisclosed. EnBiotix explicitly names Sanford Biosciences LLC in an actual USD11million convertible-note financing closed and announced December29,2021 alongside Vectura and the Cystic Fibrosis Foundation. Its successor Spexis’s May2022 corporate capital documentation also separately names the LLC as a shareholder; merger shares do not constitute additional fresh investment cash. EnClear Therapies publishes the exact Sanford Biosciences wordmark among its institutional/strategic partners. A current partner listing alone does not establish a specific additional round or amount. Sanford Biosciences LLC is kept distinct from Sanford Applied Biosciences, the Sanford Health wholly owned biotechnology subsidiary that developed antibody-producing bovine technology subsequently acquired by SAB in June2014, as documented in SAB’s SEC filings. Neither Sanford Health nor Sanford Burnham Prebys Medical Discovery Institute is treated as this private LLC’s legal parent or duplicate cash investor. Sanford Laboratories for Innovative Medicines at sanfordlabs.org is a separately described nonprofit research institution; a secondary-directory link is not a legal alias bridge. The primary sources do not establish a rename from the Applied Biosciences company into this investment organization. The only independently verified public principal is historical T. Denny Sanford. A primary beneficiary institution confirms he died July18,2026; he is not represented as a current manager. Current investment employees, decision makers, succession arrangements, precise founding date, registered headquarters and a dedicated official investor website are not verified in accessible primary materials. The stored logo is the original exact issuer-published investor wordmark from EnClear, not the logo of a similarly named hospital or laboratory. No outside LP fund closes, AUM, nonprofit operating budgets or philanthropic gifts are represented as fund capital raised by this LLC. South Dakota’s official entity-search interface supplies no retrievable exact legal detail in this audit; a secondary listing’s inconsistent2015/2017 dates and registered-agent address are not promoted to verified founding or headquarters facts.

Isabel Cardoso is named as Head of Back and Middle Office in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Paul Watel is named as Investment Manager in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.

Alexandre Heraud is named as Partner in the still-published legacy Anaxago Capital directory. This affiliation is retained as a dated legacy disclosure; the current Ambra directory does not corroborate continued employment. No exact employment start or end day is published.